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Abbreviations 
°C – degree Celsius  
µg – microgram 
µl – microliter 
µm – micrometer 
µM – micromolar 
aa- aminoacid  
AFM – Atomic Force Microscopy 
APC – Allophycocyanin 
BCA – Bicinchoninic acid 
BLI – Bio-layer Interferometry  
BSA – Bovine serum albumin 
Butyl FF – Butyl Fast Flow column 
CNS – Central Nervous System 
DLS – Dynamic Light Scattering 
DMSO – Dimethyl Sulfoxide. 
DTT – Dithiothreitol 
FCS – Fetal Calf Serum 
FL – Full length Tau protein 
FTDP – Fronto Temporal Dementia linked with Parkinsonism 
Low-n oligomers – dimers to hexamers 
LucN – Click beetle green luciferease N-terminal sequence 
LucC – Click beetle green luciferease C-terminal sequence 
HCl – Hydrochloric Acid 
High-n oligomers - ≥15mers 
hTau40WT –Wild type full length human tau, longest CNS isoform (441 residues)  
ka – Association rate constant  
kd – Dissociation rate constant  
KD – Dissociation constant (kd / ka) 
mA – milliAmpere 
mAb – Monoclonal antibody 
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MAP – Microtubule Associated Protein 
mg – milligram 
ml – milliliter 
mm – millimeter 
mM – millimolar 
mTau40 – Full length mouse tau, longest CNS isoform 
MWCO – Molecular Weight Cut Off 
NaN3 – Sodium Azide 
NFT – Neurofibrillary Tangles 
ng – nanogram 
nm – nanometer 
nM – nanomolar 
NMR – Nuclear Magnetic Resonance 
OD – Optical Density 
PAGE – Polyacrylamide Gel Electrophoresis 
PBS – Phosphate Buffer Saline 
PHF – Paired Helical Filaments 
PNS – Peripheral Nervous System 
PVDF – Polyvinylidenedifluoride 
RD – Repeat domain of tau protein  
Rpm – Rotations per minute 
RT – Room temperature 
s – second 
SDS – Sodium Dodecyl Sulfate 
SEC – Size Exclusion Chromatography 
TauRDΔK – Tau Repeat Domain protein with deletion of lysine 280 
TauFLΔK – Full length human tau with deletion of lysine at 280 position 
TEA – Triethanolamine 
ThS – Thioflavin S 
V – Volt 
WT – Wildtype
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Summary 
Tau, a microtubule associated protein, forms abnormal aggregates in many 
neurodegenerative diseases such as Alzheimer disease (AD). There is an urgent need for 
disease-modifying therapies of AD and related tauopathies. Inhibiting the aggregation of 
tau and the accumulation of neurofibrillary tangles (NFTs) could be helpful in combating tau 
pathology. Recent studies show that tau induced toxicity is mainly due to the presence of 
oligomers of tau rather than the monomers and fibrillar aggregates (Kaniyappan et al., 
2017, Flach et al., 2012, Lasagna-Reeves et al., 2010).  
To combat the toxicity of tau oligomers we developed antibodies against the purified low-n 
tau oligomers (dimers to hexamers) of TauRDΔK, the strongly aggregating repeat domain of 
tau. Monoclonal antibodies were tested by various biochemical and biophysical methods 
for their specificity to bind to the toxic oligomers. Some antibodies show specificity to 
aggregates of tau while others detect all forms of tau. Antibodies 2B10 and 6H1, described 
as representative examples, bind to tau oligomers with high specificity as judged by dotblot, 
dynamic light scattering (DLS) and immunofluorescence analysis. As these antibodies are 
dependent on tau conformations, they appear non-specific in denaturing methods like 
western blotting. 2B10 and 6H1 antibodies are able to inhibit the tau aggregation up to 
~90% in vitro (TauRDΔK, hTauP301L), as judged by the Thioflavin S fluorescence assay which 
is sensitive to β-structure. In the presence of antibodies tau protein forms only up to low-n 
oligomers as judged by light scattering and atomic force microscopy (AFM). The choice of 
the pH of the column elution buffer of the antibodies plays a key role in determining the 
activity of the antibodies, as antibodies eluted at low pH have a higher activity compared to 
the same antibodies eluted at high pH.  
The ability of antibodies to inhibit the aggregation of tau was tested in an N2a cell model of 
tau pathology which expresses the pro-aggregant tau repeat domain TauRDΔK. Antibodies 
were added to the extracellular medium, without or with protein transfection reagent (Xfect) 
which stimulates cellular uptake. In this assay, 2B10 antibody failed to inhibit tau 
aggregation (ThS signal) and failed to prevent aggregation induced apoptosis (Annexin V 
signal). By contrast, in the split-luciferase complementation assay the antibody 2B10, 
applied extracellularly, was able to prevent the dimerization/oligomerization of tau. 
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Surprisingly this antibody has only a relatively low affinity to tau but is still very active in 
inhibiting tau aggregation in vitro. Antibodies added extracellularly were taken up by the 
cells and sorted into lysosomes. Their inhibitory effect can be explained by the fact that the 
internalized antibody recruits the toxic tau protein or oligomers to the lysosomes for 
degradation (Figure 0.1). In summary, a subset of antibodies raised against the purified 
low-n oligomers of TauRDΔK are able to inhibit tau aggregation both in vitro and in a cell 
model of tau pathology. 
 
Figure 0.1: Mode of activity of anti-tau low-n oligomer antibodies 
Cartoon representation of the modes of activity of the anti-tau low-n oligomer antibodies. Extracellularly 
added antibodies enter the N2a cells expressing TauRDΔK and are released into the cytosol by some 
unknown mechanism (either receptor mediated or bulk endocytosis, dotted arrows) where they interact 
with tau oligomers and promote their entry into lysosomes presumably for degradation. 
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1 Introduction 
1.1 Neurodegenerative diseases 
Neurodegenerative diseases are a group of diseases in which loss of structure and function 
of neurons results in cell death. Aging is an important risk factor for many 
neurodegenerative diseases (Brookmeyer et al., 1998). The majority of the 
neurodegenerative diseases are proteinopathies which are characterized by the 
accumulation of misfolded and insoluble filamentous protein aggregates (Przedborski et al., 
2003). These proteinopathies are called amyloid diseases, as the filamentous aggregates 
display amyloid properties (cross- β-pleated sheet structures). Brain amyloidoses display 
phenotypic diversity. Even though amyloidogenic proteins are typically expressed 
systemically, they accumulate in specific regions of the brain and their aggregates are 
composed of different protein constituents (Skovronsky et al., 2006). An example is 
Alzheimer disease (AD), the most prevalent form of neurodegenerative diseases which is 
characterized by the deposition of extracellular plaques composed of amyloid-β and 
intracellular tangles containing aggregates of tau protein.  
1.2 Tauopathies 
Tau, a microtubule-associated protein (MAP), was discovered in 1975 (Weingarten et al., 
1975). Tau occurs mainly in the brain, particularly in the axons of mature neurons, but 
traces can be detected in glia as well (Miller et al., 2004). Tau plays a major role in binding, 
stabilization and assembly of microtubules (Mandelkow and Mandelkow, 2012). Tau is a 
highly soluble (hydrophilic) and natively unfolded protein with little or no tendency to 
aggregate (Jeganathan et al., 2008). In disease conditions, tau accumulates to form 
insoluble, fibrillary deposits in a wide range of neurodegenerative diseases called 
tauopathies (Wang and Mandelkow, 2016). AD is the best-known form of tauopathy, but 
aggregation or accumulation of abnormal tau occurs also in other tauopathies, such as 
Frontotemporal dementia with Parkinsonism linked to Chromosome 17 (FTDP-17), 
Corticobasal degeneration (CBD), Progressive Supranuclear Palsy (PSP), Argyrophilic 
Grain Disease (AGD), Huntington Disease (HD), Pick Disease (PiD) and Traumatic Brain 
Encephalopathy (TBE). The ability of tau to cause neurodegenerative diseases has been 
confirmed by the identification of tau mutants in patients with FTDP-17 which indicates that 
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mutations in the tau gene are sufficient to trigger neurodegeneration (Spillantini et al., 
2000). The trigger for tau aggregation and the mechanisms involved in tau-induced 
neurodegeneration are still poorly understood. Over the years, several research groups 
have created transgenic mouse lines with different tau mutations (P301L, P301S, ΔK280, 
G272V, A152T) to study the pathophysiology and role of tau in neurodegenerative diseases 
(Mocanu et al., 2008, Ramsden et al., 2005, Yoshiyama et al., 2007, Sydow et al., 2016, 
Alonso. et al., 2004, Eckermann et al., 2007, Van der Jeugd et al., 2012).  
1.3 Tau 
Human tau is encoded by the microtubule-associated protein tau gene (MAPT), which is 
located on chromosome 17q21 and comprises 16 exons (Neve et al., 1986). Transcribed 
RNA undergoes alternative splicing which produces different mRNA species which 
translates to different tau isoforms. The human brain contains six tau isoforms which differ 
in their presence or absence of N-terminal (0N, 1N, 2N) and C-terminal (R2) inserts which 
are encoded by the alternative splicing of the exons E2, E3 and E10 (Figure 1.1). Tau 
isoforms with exon 10 are called 4R tau as they have 4 repeats and tau isoforms lacking 
exon 10 are called 3R tau as they have only 3 repeats (lacking R2) (Avila et al., 2004). 
Exons 2 and 3 encode two N-terminal inserts of tau. Exons 2 and 3 are also alternatively 
spliced, exon 2 can appear alone, but not exon 3 (Andreadis et al., 1995).  There is an 
additional tau isoform in the peripheral nervous system which is encoded by an extra exon, 
exon 4a. It is also referred to as "big tau" because of additional 242 residues (Goedert et 
al., 1992). 
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Figure 1.1: Tau gene and protein organization 
Diagram showing the MAPT gene encoding human tau located on chromosome 17 at position 17q21.31. 
The tau gene contains 16 exons. The start and stop codons are present in the exon 1 and 13 respectively. 
The human CNS contains six major tau isoforms which differ in their presence or absence of near  
N-terminal inserts (1N, 2N) and near-C-terminal (R2) inserts which are encoded by the alternative splicing 
of the exons E2, E3 and E10 (green, yellow and red).  8 out of 16 exons (E1, E4, E5, E7, E9, E11, E12 and 
E13) are constitutive. Removal of exons 2, 3, 4a, 6, 8, 10 by alternative splicing results in different protein 
isoforms (Andreadis, 2005, Andreadis, 2006). Exons 4a, 6 and 8 are not transcribed in CNS. Exons -1 (part 
of 5’ UTR) and 14 (part of 3’UTR) are transcribed but not translated (Lee et al., 2001). In PNS (peripheral 
nervous system) exon 4a alone or in combination with exon 6 encode a larger tau isoform called big tau. 
There is no evidence for tau isoforms containing exon 8.  Expression of tau isoforms is developmentally 
regulated. Adult human brain contains six main isoforms and the fetal brain expresses only the shortest 
isoform. The ratio of 3R and 4R tau are almost equal in adult brain. Figure adapted from (Wang and 
Mandelkow, 2016). 
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1.3.1 Tau domains 
The six main tau isoforms in human brain range from 352-441 residues with the molecular 
weight (Mr) ranging from 36.7-45.7 kDa but the tau isoforms run on 12% SDS gel show an 
apparent Mr ranging from 45-65 kDa, as the protein is natively unfolded. Tau protein can 
be subdivided into various domains, depending on protein interactions and composition 
(Gustke et al., 1994). Chymotryptic cleavage at Y197 generates a carboxy-terminal 
fragment which binds to microtubules and promotes their assembly (assembly domain), 
and an amino-terminal fragment which projects away from the microtubules (projection 
domain). The N-terminal region is highly charged (acidic region 1-120, basic region  
120-150), followed by a proline rich region (residues 150-240, also basic). This is followed 
by the basic repeat domain (244-368) consisting of 3 or 4 pseudo-repeats of 31 or 32 
residues. Residues 369-400 (R’ or 5th repeat) are followed by the acidic C-terminal tail 
(residues 401-441) (Gustke et al., 1994). The repeat domain is important for pathological 
aggregation (notably the hexapeptide motifs at the beginning of R2 and R3 which have a 
high propensity for β-structure (von Bergen et al., 2000)). The repeat domain plus adjacent 
flanking domains are required for strong microtubule binding (Mandelkow and Mandelkow, 
2012). 
1.3.2 Tau structure 
The primary structure reveals tau as an unusually hydrophilic, highly soluble and natively 
unfolded protein (Lee et al., 1988). The disordered nature of tau is maintained in the  
N-terminal and C-terminal domains of tau without contributing to microtubule binding 
(Jeganathan et al., 2008). Tau belongs to the class of intrinsically disordered proteins with 
little detectable secondary structure by circular dichroism (CD) and Fourier transform 
infrared spectroscopy (FT-IR) (Schweers et al., 1994, Mukrasch et al., 2009, von Bergen 
et al., 2005). Because of this property, tau is resistant to high temperatures and acidic 
conditions which is used as basis for its preparation in vitro. Because of its unfolded 
structure tau cannot be studied by X-ray crystallography (Fischer et al., 2007) but NMR 
studies confirm its disordered structure (Mukrasch et al., 2009). Because of its flexibility tau 
is able to bind to many proteins in the cell. In solution amino and carboxy terminals of tau 
fold over the repeat domain, forming a “paperclip” -like structure (Jeganathan et al., 2006). 
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Figure 1.2: Structure of tau filaments in AD and Pick disease 
A) Sequence alignment of the repeat domain (R1-R4) showing the differences in the β-strand regions 
between the Alzheimer fold (eight β-strands) and Pick fold (nine β-strands). B) Cryo-EM structures of tau 
filaments from AD. Cryo-EM density and atomic models of PHFs (blue) and straight filaments (green). Red 
arrows indicate additional densities in contact with K317 and K321. C) Secondary structure elements in the 
Pick and Alzheimer folds. The positions of Cys322 (yellow ‘C’) and Asp348 (red ‘D’) in the two folds are 
highlighted. The asterisk and hash symbols mark conserved turns of homologous regions in the Pick and 
Alzheimer folds. Red stars indicate epitopes of antibody DC8E8 capable of disrupting filament formation 
and used for developing the AADvac1 vaccine (Kontsekova et al., 2014). The epitopes lie close to the 
repetitive PGGG motifs at the end of each repeat. Figure adapted from (Falcon et al., 2018, Fitzpatrick et 
al., 2017). 
Recently, partial structures of tau aggregated into paired helical filaments have been solved 
by cryo-electron microscopy and image reconstruction. They confirm earlier results from 
spectroscopic and x-ray experiments about the prominence of β-structure in the repeat 
domain (Figure 1.2). The structures reveal distinct folds in the repeats and differences 
between disease types (e.g. Alzheimer vs. Pick disease) (Fitzpatrick et al., 2017, Falcon et 
al., 2018).  
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1.3.3 Cellular functions of tau 
A major role of tau or other MAPs is to support the assembly of microtubules. These are 
involved in diverse cellular functions like cell division, segregation of chromosomes, 
outgrowth of cell processes, and intracellular transport of vesicles by motor proteins. Tau 
maintains the dynamic instability of microtubules that allows reorganization of the 
cytoskeleton (Mandelkow and Mandelkow, 2012). In adult neurons tau is localized mainly 
in axons where it binds to the outer surface of microtubules. The repeat region of tau  
(R1-R4) form the core of the microtubule binding region, but strong binding requires 
additionally the flanking regions N and C-terminal of the repeats. Tau with more repeats 
(4R) have stronger affinity to microtubules than the tau with less repeats (3R) (Goode et 
al., 2000, Gustke et al., 1994). The affinity of tau to microtubules can be influenced by post-
translational modifications like phosphorylation, acetylation, glycosylation etc. (Martin et al., 
2011, Wang and Mandelkow, 2016). Especially the phosphorylation of S262 in R1, 
phosphorylated by the kinase MARK, decreases the affinity of tau to microtubules strongly 
(Biernat et al., 1993, Schwalbe et al., 2013). 
Tau is also involved in various other functions apart from binding to microtubules. Tau 
competes with the motor protein dynein and kinesin in binding to the microtubules and 
decreases the motile fraction of motor proteins and their run length, thereby decreasing the 
anterograde and retrograde transport (Stamer et al., 2002). Tau interacts with other 
cytoskeletal fibers, e.g. actin filaments, intermediate filaments and spectrin which may allow 
microtubules to interconnect with other cellular structures (Cabrales Fontela et al., 2017, 
Mandelkow and Mandelkow, 2012). 
1.3.4 Tau aggregation 
Although Tau is natively unfolded and highly soluble (>200 µM in cells (Tepper et al., 
2014)), it can be induced to aggregate into well-structured fibers in neurodegenerative 
diseases like AD. The inducers for tau aggregation in vivo are still not well established, but 
likely candidates are extended polyanions (e.g. RNA, acidic proteins, and heparin) because 
these are capable of stimulating tau aggregation in vitro (Goedert et al., 1996, Kampers et 
al., 1996). Consistent with this, the cationic repeat domain of tau forms the core of tau 
fibers. This domain is also important for the binding of tau to the anionic surface of 
Introduction  
16 
 
microtubules, illustrating that the physiological and pathological roles of tau are encoded in 
the same domain. PHF formation is facilitated by two hexapeptide motifs with enhanced 
propensity for β-structure, located in repeat R2 (PHF6*- 275VQIINK280) and in R3  
(PHF6- 306VQIVYK311). They play a key role in forming the β-sheet structures necessary for 
the aggregation process and pathological inclusions (von Bergen et al., 2000, von Bergen 
et al., 2001, von Bergen et al., 2005). The formation of PHF’s can be influenced by many 
factors like mutations, post-translational modifications and biochemical modifications of tau 
protein. For instance, sulphated glycosaminoglycan like heparin sulfate compensates the 
basic charge of tau and thus enables PHF formation. Lipid micelles like arachidonic acid 
and polyanions like RNA increase tau self-assembly by overcoming the nucleation barrier 
(Wilson and Binder, 1997, Kampers et al., 1996). Phosphorylation of tau is the major  
post-translational modification of tau. Because of the protein's disordered structure and 
multiple potential sites (> 80), many protein kinases can phosphorylate tau (Noble et al., 
2013, Stoothoff and Johnson, 2005, Mandelkow and Mandelkow, 2012, Hanger et al., 
2009). However, the contribution of phosphorylation to PHF aggregation is still a matter of 
debate since even highly phosphorylated tau can remain soluble in cells (Tepper et al., 
2014). Oxidation of cysteines C291 and C322 (in R2 and R3) to form intra-chain disulfide 
bridges retards aggregation, whereas inter-molecular bridges (C322-C322) can enhance 
the aggregation propensity of tau (Schweers et al., 1995).  
Mutations in the tau gene are correlated with FTLD disorders, presumably by enhancing 
the β-propensity of tau and thereby promoting tau aggregation. Since the repeat domain of 
tau forms the core of the PHFs (Mukrasch et al., 2009), mutations in the repeat domain can 
induce a strong conformational change in repeat 2 and promote aggregation. FTDP-17 
mutants in the repeat domain, like the ΔK280 or P301L, strongly promote the aggregation 
of tau into PHFs (Barghorn et al., 2000). Indeed, the ΔK280 mutation in the repeat domain 
construct K18 can promote slow aggregation even without any inducers in vitro, illustrating 
the strong influence of mutations in inducing and accelerating tau aggregation (Barghorn 
et al., 2000, von Bergen et al., 2001, Kaniyappan et al., 2017). The β-structure in tau has 
been verified by various biophysical techniques (Mukrasch et al., 2005, Barghorn et al., 
2004). Introducing anti-aggregant mutations which prevent β-structure in the hexa-peptide 
motifs lead to blockage of tau aggregation. This confirms that the formation of β-structure 
is necessary for tau aggregation (von Bergen et al., 2000). 
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1.3.5 Tau-dependent toxicity 
Tau gene mutations reported in FTDP has confirmed the role of tau in neurodegeneration 
(Spillantini et al., 1998). Various studies suggest the correlative association of tau 
aggregation with neuronal dysfunction and neurodegeneration (Ramsden et al., 2005, 
Yoshiyama et al., 2007, Mocanu et al., 2008). Elevated tau levels alone can initiate neuronal 
dysfunction which is clearly evident in transgenic worm, fly, and mouse models of tau 
pathology (Andorfer et al., 2005, Sydow et al., 2011, Pir et al., 2016). Regulatable tau 
transgenic animals and cell models expressing the pro-aggregant repeat domain of human 
tau (TauRDΔK) show pronounced aggregation and cause severe neuronal dysfunction 
inducing memory deficits (Mocanu et al., 2008, Pickhardt et al., 2017). However, when the 
expression of pro-aggregant human tau in transgenic mouse models is switched off the tau 
pathology is reduced and memory is recovered (Sydow et al., 2011). In contrast, introducing 
two proline mutations (I277P/I308P, breakers of β-structure) in the hexapeptide motifs of 
R2 and R3 prevents  tau aggregation, so that this anti-aggregant mouse model does not 
show abnormalities (Mocanu et al., 2008). These data suggests that tau aggregation  
(β-sheet conformation) causes toxicity. In the case of the regulatable transgenic mouse 
model expressing full length human tau with the pro-aggregant mutation ΔK280 (hT40ΔK280) 
at a low level (1X endogenous mouse tau) synaptic loss and memory deficits are 
detectable, but aggregation is slow and reaches only the "pre-aggregate" stage 
(Eckermann et al., 2007, Van der Jeugd et al., 2012). These data suggest that pre-NFTs or 
smaller species of tau (oligomers) are likely the toxic species. 
Tau oligomers have been reported to cause cell death, synaptic dysfunction and memory 
deficits when injected into the brains of wild type mice (Lasagna-Reeves et al., 2011). Some 
tau oligomer preparations have been reported to decrease cell viability and increase 
phospholipid vesicle leakage in SH-SY5Y cells (Flach et al., 2012). On the contrary, other 
authors reported that tau oligomers can induce synaptotoxicity without affecting the cell 
viability (Kaniyappan et al., 2017).These discrepancies may be related to different methods 
of oligomer preparation and observation of effects. Methods included the  preparation of 
tau oligomers in vitro such as cross-seeding with Aβ42 oligomers (Lasagna-Reeves et al., 
2010), or oligomerization in the presence of arachidonic acid or heparin (Patterson et al., 
2011, Flach et al., 2012). The uncertainty of oligomer preparations from the above reported 
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preparations is that tau oligomers might not mimic the natural oligomers as they are induced 
to aggregate in vitro with some inducers like heparin, arachidonic acid micelles and Aβ42 
oligomers. In our studies we prepared oligomers using the pro-aggregant tau repeat domain 
without any inducers (Kaniyappan et al., 2017) in order to mimic the oligomers in disease 
conditions. Because of the toxic properties of tau oligomers, they can be potential targets 
for therapeutic studies. Small drug molecules or antibodies can be designed to counteract 
the toxicity caused by tau oligomers.  
1.4 Approaches to disease modifying therapies 
AD is the most common form of dementia, affecting worldwide around 36 million people 
currently and expected 96 million people by 2050 (Reitz and Mayeux, 2014). AD is 
characterized by the presence of extracellular plaques composed of Aβ and intracellular 
tangles of tau. Disease modifying therapy is an intervention in the clinical progression of 
the disease by interfering with the pathophysiological mechanisms of the disease leading 
to cell death (Cummings and Fox, 2017). In AD, the disease progression could be retarded 
by blocking the pathogenic process like aggregation of Aβ or tau, inflammation, oxidative 
damage, cholesterol metabolism, and others. Several therapies have been tried with the 
aim of targeting Aβ pathology (Liu et al., 2018, Honig et al., 2018), but so far they have 
failed to show significant benefits in clinical trials (Nelson et al., 2012). Therefore therapies 
targeting tau pathology have gained importance, especially as cognitive decline in AD 
correlates better with tau pathology than with amyloid burden (Huber et al., 2018, Reas, 
2017). Disease modifying therapies targeting tau pathology could include the interference 
with tau aggregation by aggregation inhibitor drugs, reduction of tau levels by drugs or 
antisense oligonucleotides, gene therapy targeting tau gene, active/passive immunization 
to neutralize toxic tau species, and others. A brief summary of different therapies that have 
been explored for tau pathology in animal models are presented below. 
1.4.1 Therapies targeting kinases  
Tau becomes "hyperphosphorylated" at several sites in AD, and it is assumed that 
hyperphosphorylated tau has a weaker affinity to microtubules and greater propensity to 
aggregate and form NFTs (Avila, 2006). This provides the rationale for down-regulating 
kinases which phosphorylate tau or upregulate phosphatases. Tested kinases include 
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GSK3β, CDK5, p38, MARK, PKA etc. (Mandelkow and Mandelkow, 2012, Tell and 
Hilgeroth, 2013). GSK3β is increased (Pei et al., 1997) and co-localized with NFTs in AD 
brain (Leroy et al., 2007). Lithium inhibits GSK3β and reduces tau pathology in transgenic 
mice (Engel et al., 2006). However, treatment of patients with mild AD did not show any 
improvement in cognitive performance (Hampel et al., 2009). Another GSK3β inhibitor  
(SB-216763) was shown to decrease phospo-tau in mice, but  had toxic effects 
(Boutajangout and Wisniewski, 2014). Another example is the microtubule-affinity 
regulating kinase (MARK) which phosphorylates tau at S262 (KXGS motif) and decreases 
the affinity of tau to microtubules (Biernat et al., 1993, Drewes et al., 1997). Our group 
showed four low-molecular weight anti-MARK2 compounds (30019, 30195, 30197, 30199) 
sharing a common 9-OXO-9H-acridin-10-yl functional group which inhibited the MARK2-
mediated hyperphosphorylation of tau (Timm et al., 2011). Overall, the interest in kinase 
inhibitors to combat AD has waned since positive effects observed in transgenic animals 
have not been reproduced in patients, and since interference with the network of kinases 
may lead to unpredictable results. 
1.4.2 Therapies targeting inhibition of tau aggregation 
As tau aggregates in a pathological manner in AD, combating tau pathology would be 
expected to be beneficial. A number of potential drugs to inhibit the aggregation of tau  
in vitro and in cell or animal models have been described (Pickhardt et al., 2005, Bulic et 
al., 2013). The phenothiazine compound methylene blue, which penetrates the blood brain 
barrier (BBB), has been shown to inhibit tau aggregation in vitro and in animals (Wischik et 
al., 1996, Hochgrafe et al., 2015). However, despite extensive efforts, this and related 
compounds (LMTX) have failed in human trials (Gauthier et al., 2016). Rhodanine based 
inhibitor bb14 inhibits tau aggregation in vitro and in organotypic hippocampal slice cultures 
(OHSCs) expressing pro-aggregant tau (Pickhardt et al., 2015, Messing et al., 2013). The 
phenylthiazolylhydrazide based inhibitor BSc3094 is effective in reducing aggregation in 
N2a cells expressing pro-aggregant tau and also in worms (Pickhardt et al., 2007b, 
Fatouros et al., 2012). A naturally occurring compound curcumin reduces tau aggregation 
by binding to β-sheet conformation (Rane et al., 2017). In animal models curcumin 
decreases both tau and Aβ pathology and ameliorates behavioral and synaptic deficits (Ma 
et al., 2013, Shytle et al., 2012). The antioxidant and anti-inflammatory properties of 
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curcumin, as well as its safety in humans, make it an attractive candidate for clinical 
development. It is currently under clinical trial phase II (Congdon and Sigurdsson, 2018).  
1.4.3 Therapies targeting clearance of tau aggregates 
Another approach directed at tau pathology is to enhance the degradation of polymerized 
tau. As a fact, heat shock protein 90 (HSP 90) is involved in re-folding of the denatured 
proteins for their degradation. In case of tau, HSP 90 fails to regulate tau protein and  
prevents tau from degradation (Blair et al., 2014). EC102, an Hsp90 inhibitor promoted 
selective decrease of phospho-tau species in a transgenic mouse model of AD (Dickey et 
al., 2007). Similarly, the antibiotic Geldanamycin (GA) inhibits HSP90 and reduces 
phospho-tau levels, although with a high degree of toxicity (Blair et al., 2014). Another 
HSP90 inhibitor, 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) decreases NFTs in 
a mouse model of tauopathy. This compound has already been in clinical studies for cancer 
treatment (Ho et al., 2013). The co-chaperone Aha1 enhances the HSP90 ATPase activity 
and dramatically increases tau aggregation. Accordingly, the Aha1 inhibitor KU-177 
reduces the accumulation of insoluble tau (Shelton et al., 2017).  
1.5 Tau immunotherapy 
Treatments aimed at reducing amyloid-β or tau pathology (aggregation inhibition) appeared 
to be promising in animal models (Hosokawa et al., 2012, Lai and McLaurin, 2012) but they 
failed in clinical trials (Medina, 2018, Panza et al., 2014). Immunotherapy targeting Aβ were 
also unsuccessful in clinical trials. Therefore tau based immunotherapies are expected to 
be positive and are currently in clinical trials. Since this is early days for tau 
immunotherapies, more antibodies with different targets and properties are needed (Hung 
and Fu, 2017, Nisbet and Gotz, 2018). Recent research focused on investigating new 
treatment strategies promoting the immunological clearance of tau pathology, which 
employs active and passive immunization against pathological tau. 
1.5.1 Active immunization 
Active tau immunotherapy involves eliciting an immune response against tau protein as 
immunogen to generate specific antibodies capable of binding and then reducing or 
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clearing pathological tau to ameliorate overall neuronal function. The choice of the epitope 
on tau is crucial for the success of tau immunotherapy (Pedersen and Sigurdsson, 2015). 
AADvac1 is an active immunogen containing the tau sequence 294-305 including a PGGG 
motif that occurs repetitively just upstream of the hexapeptide motifs that promote beta 
structure during aggregation. This tau sequence had been identified because it was 
targeted by a monoclonal antibody (DC8E8) capable of disrupting tau aggregation 
(Kontsekova et al., 2014). Hence the synthetic tau peptide was coupled to keyhole limpet 
hemocyanine (KLH) and aluminum hydroxide (adjuvant) to be used as a vaccine (Axon 
Neuroscience, Bratislava, Slovakia). Vaccine treated transgenic animals showed reduced 
tau oligomerization, phosphorylation and improved sensorimotor functions. This treatment 
did not show any adverse effects and it displayed a favorable safety and tolerability profile 
in all toxicology studies (Kontsekova et al., 2014). AADvac1 was the first anti-tau vaccine 
to enter human trial phase 1.  Phase 2 clinical studies started for AADvac1, which includes 
cognitive and clinical assessments with exploratory outcomes of CSF biomarkers (Medina, 
2018, Novak et al., 2017). 
During the events leading to neurofibrillary pathology, tau undergoes numerous  
post-translational modifications such as phosphorylation, truncation, glycosylation and 
ubiquitination (Martin et al., 2011). Phospho-tau as an epitope has received the most 
attention for both active and passive immunotherapy. ACI-35 is a liposomal active vaccine 
with the adjuvant monophosphoryl lipid A (MPLA) developed by AC Immune (Lausanne, 
Switzerland). It is a palmitoylated phospho-tau synthetic peptide which has 16-amino acids 
corresponding to human tau sequence 393–408, with phosphorylated residues S396 and 
S404, which become hyperphosphorylated in AD and form the basis of the diagnostic 
antibody PHF-1 (Greenberg et al., 1992). In a T-cell independent immune response the 
immunogen elicits very specific tau antibodies in tau P301L mice, resulting in reduced 
phospho-tau aggregates, less tangled neurons in the brain, improvement in cognitive 
behavior and prolonged survival of ageing in tau P301L mice. These beneficial effects were 
not associated with any adverse inflammatory response or neurological side-effects, which 
suggest a good safety profile for human studies. ACI-35 (Trial ID- ISRCTN13033912) is 
currently under clinical trial phase 1b (Medina, 2018, Theunis et al., 2013). 
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Several other active immunization studies were performed. The tau peptide with residues 
417-427 containing pSer422 was tested in THY-Tau22 transgenic mice. The immunized 
mice showed a reduction in tau pathology which correlated with improved performance on 
spatial memory (Troquier et al., 2012). In another study, active immunization of transgenic 
mice expressing tau-P301L with a tau peptide containing residues 379-408 (including 
pS396 and pS404) showed a reduction in tau pathology and improved sensorimotor tasks 
compared to controls. The generated anti-tau antibodies were able to cross the blood brain 
barrier and reduce tau pathology by binding to phosphorylated tau without showing any 
adverse effects (Asuni et al., 2007). One caveat is that autoimmune reactions are a threat 
associated with active immunotherapy. Hence there is a need for more elaborate preclinical 
assessment of safety before clinical trials can be performed (Theunis et al., 2013). 
1.5.2 Passive immunization 
In passive immunotherapy, antibodies raised against tau (as antigen) are used to attenuate 
tau pathology. Several anti-tau antibodies are currently under preclinical and clinical studies 
for treatment of AD and other tauopathies. The Holtzman lab generated two series of 
antibodies against human and mouse tau (Yanamandra et al., 2013). Antibodies HJ9.3 and 
HJ9.4 detect residues 306-320 and 7-13 respectively in both human and mouse tau 
whereas antibody HJ8.5 (ABBV-8E12)  detects residues 25-30 and binds specifically to 
human tau. Antibody HJ8.5 was able to inhibit the transfer of pathology in a trans-cellular 
propagation assay. Chronic intracerebroventricular (ICV) injection of antibodies in P301S 
mice showed a prominent decrease in hyperphosphorylated tau and reversal of behaviour 
deficits in the contextual fear conditioning test (Yanamandra et al., 2013). Phase 1 studies 
showed an acceptable safety and tolerability profile of single doses of ABBV-8E12 (West 
et al., 2017). A phase 2 trial on PSP subjects is still ongoing (Budur et al., 2017). 
Antibodies developed against phosphorylated tau have also been explored in pre-clinical 
experiments. The efficacy of tau based immunotherapy has been tested by injecting the 
phospho-tau specific PHF1 antibody (pS396 and pS404) intraperitoneally in the JNPL3 
mouse model which prevented the tau pathology and functional impairments (Boutajangout 
et al., 2011). Similar studies were done with antibodies against PHF1 and MC1 epitopes in 
two other mouse models (JNPL3 and P301S). Passive immunization of these two 
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antibodies showed the prevention of tau pathology as well as a reduction of neurofilament 
positive axonal spheroids in the spinal cord with an improvement in locomotor activity. 
Despite the fact that both antibodies (PHF1 and MC1) have different epitopes they yielded 
similar phenotypic improvement (Chai et al., 2011). 
Passive tau immunotherapy not only enables recovery of animals from tau pathology but 
also retards Aβ pathology in some AD models of tau + Aβ pathology. Anti-tau antibodies 
4E6 (raised against residues 6-18 of tau) and 77E9 (against residues 184-195) raised 
against the N-terminal domain of tau injected in 3XTg AD mice showed reduced levels of 
total tau and hyperphosphorylated tau with improved cognitive performance. Antibody 
treated animals also showed a decreased amyloid precursor protein (APP) and amyloid 
plaques (Dai et al., 2015, Dai et al., 2017).  
One study clearly highlighted the choice of antigen used to generate therapeutic antibodies. 
A comparative study of the efficacy of pan tau antibody with two phospho-tau (pS404) 
specific antibodies with similar affinity but different isotypes (IgG1/k and igG2a/k) showed 
differences in their efficacy (Ittner et al., 2015). A reduction in tau-positive neurofibrillary 
inclusions and pS422-positive tau was observed in the mice treated with the IgG2a/k pS404 
antibody. A trend towards reduction of pS422-positive tau was observed with the IgG1/k 
pS404 antibody, whereas no reduction was observed in the pan-tau antibody-treated mice. 
This study suggests that the activity of antibodies is dependent on the isotype and 
specificity of the antibody (Ittner et al., 2015). Thus there is a need for careful consideration 
of antibody design, affinity, specificity and efficacy for immunotherapy. 
Some antibodies were raised against certain oligomeric species of tau (T22, TOMA-tau 
oligomeric monoclonal antibody, both oligomer specific conformation dependent 
antibodies), or TOC1-tau oligomeric complex 1 (recognizing tau oligomers at residues  
209-224) (Lasagna-Reeves et al., 2012, Castillo-Carranza et al., 2014b, Ward et al., 2013) 
which show strong affinity to tau oligomers without binding to monomers or polymers of tau. 
Treatment of tau tg-mice with TOMA antibody resulted in lower cognitive and behavioral 
deficits compared with un-treated animals. There is a need for further characterization of 
these antibodies regarding their specificities as the specificity of T22/TOMA antibody is still 
a matter of debate. 
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All the approaches of tau-directed therapy mentioned above are currently in late-stage  
pre-clinical development and likely to enter clinical trials in the near future. Other promising 
tau immunotherapies are actively being studied, but it is not yet clear if those will be used 
in clinical trials (Pedersen and Sigurdsson, 2015). 
Although immunotherapy for AD is gaining popularity, there are certain pros and cons 
associated with the applications of active and passive immuninzations. Active 
immunotherapy is long lasting and cost-effective but the success of the therapy depends 
on the host immune system (which may be compromised in older animals). In passive 
immunization, the injected immunoglobulins provide immediate immunity which are 
pharmacologically controlled. However the efficacy of passive antibody therapies is limited 
by the half-life time of the immunoglobulins, resulting in the need for regular reinjections 
and enormous costs. One great advantage of passive immunotherapy is that it can be 
discontinued at any point of time unlike active immunization. These factors should also be 
taken into consideration for a successful immunotherapy (Jensen-Jarolim and Singer, 
2011). 
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1.6 Aims of the study 
Tau aggregation is known to correlate well with the disease progression in AD (Braak and 
Braak, 1991b, Braak and Del Tredici, 2016). Inhibiting tau aggregation might overcome the 
tau induced pathology in AD. Cell and animal models expressing pro-aggregant forms of 
tau display AD-like tau pathology, whereas anti-aggregant forms do not (Khlistunova et al., 
2006, Sydow et al., 2011). Moreover, the toxicity of tau appears to reside in the early 
oligomeric forms of tau (Kaniyappan et al., 2017). Therefore the aim of the current study is 
to develop novel antibodies against toxic species and conformations  
(low-n oligomers) of TauRDΔK which can be of therapeutic application for diagnosis or 
treatment (passive immunotherapy) of transgenic animal models, with the aim of future 
applications to human patients.   
The current study addresses the following questions: 
1. Generation of antibodies against toxic species of tau (antigen) and screening them 
for inhibition of tau aggregation. 
2. Determination of the specificity and affinity of the antibodies against low-n oligomers 
of tau. 
3. Characterization of antibodies (in terms of their specificity and stability) that can 
block tau aggregation to a high degree (>90%) in vitro and ex vivo. 
4. Characterization of the ability of antibodies to neutralize the tau induced toxic effects 
in an N2a cell model of tauopathy.  
5. Analysis of the mechanism of antibody-mediated inhibition of tau-aggregation in N2a 
cell model of tauopathy. 
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2 Materials and Methods 
2.1 Materials (instruments & equipment) 
2.1.1 Centrifuges 
Name Company 
Eppendorf centrifuge 5415C Eppendorf, Hamburg 
Eppendorf centrifuge 5810R Eppendorf, Hamburg 
Eppendorf centrifuge 5810 Eppendorf, Hamburg 
OptimaTM LE-80K Ultracentrifuge Beckman Coulter, München 
AvantiRCentrifuge J-26 XP Beckman Coulter, München 
OptimaTM Max Ultracentrifuge Beckman Coulter, München 
2.1.2 HPLC 
Name Company 
Äkta explorer100 GE Healthcare Life Sciences, Freiburg 
2.1.3 Columns 
Name Company 
Superdex G200 HR 16/60 Amersham Biosciences, Freiburg 
SP Sepharose 16/10 Amersham Biosciences, Freiburg 
HiPrep Butyl FF 16/10 GE Healthcare Life Sciences, Freiburg 
NAP5 column Pharmacia Biotech, USA 
PD 10 column Pharmacia Biotech, USA 
2.1.4 Spectrophotometers 
Name Company 
Ultrospec 3100 pro Amersham Biosciences, Freiburg 
Tecan Spectrophotometer Lab System, Frankfurt 
Dynamic Light Scattering Nano S MALVERN, Germany 
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2.1.5 Microscopes 
Name Company 
Atomic Force Microscope  
(Nanowizard 3) 
JPK instruments, Germany 
LSM 700 Confocal Microscope Zeiss, Germany 
2.1.6 Cell culture equipment 
  Name Company 
HERA Safe Laminar air flow Heraeus Instruments, Germany 
HERA Cell 240 CO2Incubator Heraeus Instruments, Germany 
Neubauer chamber MARIENFELD, Germany 
2.1.7 Others 
Name Company 
French Press G-Heinemann Ultraschall und 
Labortechnik, Germany 
Ice flaking machine (SPR 80) Nord Cap, Germany 
Water filtration apparatus Millipore, Germany 
Deep freezer (-80°C) SANYO, USA 
Image Quant LAS 4000 mini GE Healthcare Life Sciences, Freiburg 
Blotting Apparatus BIO-RAD trans-blot SD transfer cell 
Gel apparatus for SDS-PAGE SE 250, Hoefer, USA 
Electrophoresis power supply Pharmacia Biotech, USA 
Micropipettes (2, 10, 20, 100, 200 and 
1000µl) 
GILSON, Austria 
Weighing balance BP 310S Sartorius, Germany 
Incubators Memmert, Germany 
Incubator with shaker INFORS HT Multitron, Switzerland 
Heating-agitator Eppendorf, Germany 
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Incubator with rotator Shake and Stack, HYBAID, Germany 
Laminar flow for bacterial inoculation LaminAir HB 2448, Heraeus 
Instruments, Germany 
pH-Meter Schott Instruments, Germany 
Water bath GFL AND JULABO UC, Germany 
Vortexer JANKE & KUNKEL. IKA-WERK, 
Germany 
Pasteur pipette Assistant, UK 
well plates (6,12,24,48, and 96) Corning, Germany 
SNL 10 cantilever Bruker, München 
Glass wares VWR international, UK 
PVDF membrane (0.45µm pore size), Millipore, Germany 
Quartz microcuvettes Hellma, Muhlheim, Germany 
Magnetic steel disks (diameter 12mm) Ted Pella, Inc., Redding, CA, USA 
Teflon sheets (0.2 mm thickness) Maag Technic AG, Birsfelden, 
Switzerland 
Mica sheets Muscovite, Kolkata, India 
Cantilever (Si3N4) Di-Veeco, Santa Barbara, California, 
USA 
2.2 Methods 
2.2.1 Molecular biology 
2.2.1.1 Plasmid DNA isolation 
Plasmid DNA was transformed into DH5α competent cells using the heat shock 
method. Positive colonies were inoculated for the starter culture and further transferred 
to 100 ml LB medium containing respective antibiotic and cultured overnight at 37°C 
with agitation at 180 rpm. Plasmid DNA was isolated using the Endofree maxi-kit 
QIAGEN according to the manufacturer protocol. The quality of DNA was estimated by 
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running an agarose gel electrophoresis and the quantity of DNA was estimated using 
NanoDrop spectrophotometer (Peqlab ND-1000). 
2.2.1.2 Polymerase chain reaction (PCR) 
Click beetle luciferase complementation fragments were generated using the pCBG99 
plasmid (Promega). Primer designing was carried out using SnapGene 4.0 software. 
PCR amplification of N-terminal (aa 2-413) and C-terminal (aa 395-542) of pCBG99 
was performed to split the whole gene in to two parts using the following primers. 
N-terminus forward primer: 
5' CCCGGGATCCACCGGTGGTGAAGCGTGAGAAAAATGTCATCTATGGC 3'     
N-terminus reverse primer: 
5' TCTAGAGTCGCGGCCGCCTAGCCGTCGTCGTCGATGGC 3'        
C-terminus forward primer 
5' CCCGGGATCCACCGGTGAGCAAGGGTTATGTCAATAACGTTGAAG 3’             
C-terminus reverse primer 
5' TCTAGAGTCGCGGCCGCCTAACCGCCGGCCTT 3‘      
PCR reaction mixture: 
ds DNA template  20 ng (10 ng/µl) 
    Forward primer  400 nM  
   Reverse primer  400 nM  
   PCR-grade H20      15 µl 
   PWO master mix  25 µl  
Total  volume  50 µl 
PCR program 
Heat lid to 105°C 
Step Condition Temperature Time 
1. Initial denaturation 94°C 2 min 
2. Denaturation 94°C 1 min 
3. Annealing 60°C 1 min 
4. Elongation 72°C 1 min 
Repeat step 3-4 for 30 cycles 
5. Final elongation 72°C 10 min 
6. Hold 4°C Until required. 
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2.2.1.3 Restriction endonuclease digestion 
5 µg of plasmid DNA or 2 µg of PCR amplified products was mixed with 2 units of 
restriction enzymes and 5 µl of 10X fast digest green buffer (Thermo Fisher) and the 
reaction mixture was incubated at 37°C for 15 min. Restriction digestion of DNA was 
analyzed by 1% agarose gel electrophoresis.  
2.2.1.4 DNA isolation from agarose gels 
PCR amplified products or restriction digestion products run on an agarose gel were 
excised under UV light by using a clean scalpel. Excised products were purified from 
the agarose gel by using the NucleoSpin gel and PCR clean-up kit (Macherey-Nagel, 
Germany) according to the manufacturer’s instructions. 
2.2.1.5 Agarose gel electrophoresis 
0.8-1% agarose gel (depending on the size of the DNA) was prepared in 1x TAE buffer. 
5 µl of DNA ladder (Smart ladder, Eurogentec) and DNA samples were loaded on the 
gel. Horizontal gel electrophoresis was performed by using Tris-acetate (TAE) buffer 
at 80 mA for 30-60 min. Detection of DNA was performed by staining the agarose gel 
in EtBr (Ethidium Bromide) solution (4 µg/ml in H2O) for 20 min followed by detection 
using BioDocAnalyze (Biometra). 
2.2.1.6 Ligation 
Ligation of the restriction digestion products was carried out by using the DNA quick 
ligase (NEB). The ligation mix contained 50 ng of vector DNA fragment, 3-fold molar 
excess of insert DNA fragment, 1 µl of T4 DNA Ligase, 5 µl 2X ligase buffer and 0.1 µl 
100X BSA with final volume of 10 µl adjusted with elution buffer. Ligation mixture was 
incubated at RT for 5 min. 
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2.2.1.7 Transformation 
10 µl of ligation product was added to 1 vial of One Shot TOP10 chemically 
competent E. coli (In vitrogen, C4040) cells and incubated on ice for 30 min. Heat 
shock treatment was given by incubating the cells at 42°C for 50 sec and immediately 
transferring them to ice for 10 min. In the next step 200 µl of autoclaved LB medium 
were added to the cells and incubated at 37°C with shaking at 180 rpm for 1 h. Finally 
150 µl of the cells were inoculated on LB-medium plates containing 50 µg/ml 
Kanamycin antibiotic (LBK) and incubated overnight at 37°C. 
2.2.1.8 Screening for positive colonies 
Positive colonies (10-20 isolated colonies) were picked and colony PCR was done for 
the selected colonies. 4-5 positive colonies (after gel detection) were inoculated 
separately in 5 ml of LB medium containing Kanamycin (50 µg/ml) and incubated with 
shaking at 180 rpm at 37°C overnight. From the positive clones, plasmid DNA was 
purified using Qiagen Endofree mini plasmid DNA preparation kit (Qiagen, Germany) 
according to the manufacturer’s instructions and the presence of gene of interest was 
confirmed by restriction digestion that yielded the desired size of the product on the 
agarose gel. Plasmids from positive clones were sequenced by Microsynth Seqlab, 
Germany. 
2.2.1.9 DNA quantification 
The concentration of the DNA was determined by NanoDrop spectrophotometer 
(Peqlab ND-1000). Absorbance at 260 nm was used to calculate the concentration of 
nucleic acids. Elution buffer was used as buffer blank. 
2.2.2 Biochemistry 
2.2.2.1 Protein preparation and purification 
For pre-culture or starter culture, 100 ml of LB broth was prepared and autoclaved. 
Carbenicillin (50 µg/ml) was added before the inoculation of the glycerol stock of 
different tau constructs in pNG2 plasmid. This pre-culture was grown in a shaking 
incubator at 37°C with 180 rpm overnight. 2 liters of autoclaved “terrific broth” 
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containing Ampicillin (100 mg/l) was inoculated with 100 ml of pre-culture. Before 
inoculation, 2 ml of terrific broth were removed for optical density (OD) measurement 
as 0-time point control. The inoculated culture was grown at 37°C with 180 rpm rotation 
until the OD reached a minimum of 0.8 (approximately 4 h) as determined by 
spectrophotometer at 600 nm (Ultrospec 3100 pro, Amersham Biosciences, Freiburg). 
0.4 mM of IPTG was added to the culture and incubated at 37°C with 180 rpm for 3 h. 
The culture was pelleted by centrifuging at 7000 rpm for 12 min in JLA-8.1000 rotor 
(AvantiRCentrifuge J-26 XP, Beckman Coulter, München). The pellet was collected in 
90 ml of resuspension buffer and homogenized at 4°C by magnetic stirring (at this 
stage the cells can be frozen for future usage. Defrosting/thawing the cells should be 
done slowly in water at RT). The bacteria from the resuspended pellet were crushed 
twice using a French press to completely break down the cell wall, DNA, and other cell 
components. The bacteria lysates were collected in 50ml Falcon tubes. NaCl and DTT 
were added at a final concentration of 500mM and 5mM respectively. The samples 
were mixed well and boiled at 97°C for 20 min followed by centrifugation at 40,000 rpm 
(Ti 45 rotor), for 1 h at 4°C (OptimaTM LE-80K Ultracentrifuge, Beckman Coulter, 
München). The supernatant was collected and dialyzed with a 45 kDa MWCO 
membrane. The supernatant was dialyzed at 4°C twice in Mono S A buffer with an 
exchange of buffer after 2 h and second round of dialysis was done overnight. (Note: 
The volume of dialysis buffer should be at least 10 times higher than the sample 
volume). The dialyzed sample was centrifuged in a Ti 45 rotor at 40,000 rpm, for 1 h 
at 4°C. After centrifugation, the supernatant was transferred to the 150ml super loop 
and the protein purification was done by anion exchange chromatography using Äkta 
Explorer100 (GE Healthcare Life Sciences, Freiburg) system fitted with an SP 
Sepharose 16/10 column (Amersham Biosciences, Freiburg). The column was 
equilibrated prior to sample injection with 5 column volumes (CV) of Mono S A buffer. 
Once the sample was injected, the purified protein was eluted with Mono S A and Mono 
S B buffer in a gradient system (Mono S B 60% gradient for 5CV and 100% gradient 
for 1CV). The column was cleaned with Mono S B buffer for 4CV. The purified protein 
was collected in 2 ml fractions. The fractions were analyzed on a 10 or 17% SDS gel 
and stained with coomassie Blue. The protein containing fractions were pooled and 
concentrated using 3 kDa MWCO centrifugal filters (Amicon Ultra, Millipore, Ireland). 
Then the protein was further purified by gel filtration chromatography using a Superdex 
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G200 column for full length tau protein or Superdex G75 column for repeat domain tau 
protein with PBS pH 7.4, 1mM DTT as a mobile phase. The eluted protein was 
concentrated using 3 kDa MWCO amicon filters and then the protein concentration 
was measured using the BCA method. 
2.2.2.2 Protein quantification assay (BCA) 
Quantification of proteins was carried out by BCA method (BCA protein assay reagent, 
Sigma). Using known concentrations (20-200 µg/ml) of BSA a standard curve was 
prepared and the concentration of unknown protein was determined by plotting against 
known BSA concentration. BSA and other protein samples were diluted in 50µl of H2O 
and mixed with 1 ml of reagent mixture consisting of 20 µl copper (II) sulfate [4% (w/v) 
(Sigma)] and 1 ml of bicinchoninic acid solution (Sigma). Samples were incubated at 
60°C for 30 min and the absorption was measured at 562 nm using spectrophotometer 
(Ultrospec 3100 Pro Pharmachia Biotech). For the blank reference, H2O was used 
instead of the protein solution. 
2.2.2.3 Polymerization of tau protein into filaments 
To prepare filaments, different tau constructs (TauRDΔK, TauFLΔK, hT40WT) were diluted 
to 50 µM in BES buffer pH 7.0 with 1 mM DTT and heated at 95°C for 15 min, then the 
samples were cooled down to RT. 12.5 µM of heparin 16,000 was added to the 
samples and incubated at 37°C for 120 h. After 120 h the formation of filaments was 
assessed by ThS fluorescence and AFM.  
2.2.2.4 Dot blotting 
Immobilon-P membrane (Millipore) was activated by soaking it in methanol for 1 min 
and then washed 3 times with doubly distilled water and 1 time with PBS buffer. PBS 
buffer soaked Whatman filter paper was arranged on dot blot apparatus and on top of 
it activated PVDF membrane was layered. The membrane was washed thrice with  
100 µl of PBS and then 25 µl of 2 ng/µl protein in PBS buffer was loaded on the 
membrane and the buffer was imbibed using vacuum pump, during which the protein 
was retained on the PVDF membrane. The membrane was washed once more with 
200 µl of PBS buffer. Then the membrane was blocked in 5% fat dry milk powder in  
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1X TBST (containing 0.01% Tween 20) for 1 h at room temperature on an orbital 
shaker. Later the membrane was incubated with primary antibody in 1X TBST at 4°C 
overnight  on an orbital shaker or on a rotator and then the unbound or loosely bound 
antibody was washed away by washing the membrane with 1X TBST (3 times, 10 min 
each). The membrane was incubated in HRP labelled secondary antibody (1X TBST) 
at 37°C for 1 h on a rotator and the unbound antibody was washed away with 1X TBST 
buffer (3 times, 10min each). Membrane was developed using ECL reagent and the 
images were acquired using LAS ImageQuant (GE Healthcare). 
2.2.2.5 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS gels consisted of 4% acrylamide stacking gel and 10% or 17% acrylamide 
resolving gel. Protein samples were mixed with 5X SDS sample buffer and heated at 
95°C for 10 min. The electrophoresis was carried out at constant 120V for 2 h at RT in 
SDS running buffer. The gels were stained with silver stain or transferred on to a PVDF 
membrane for immunoblotting.  
2.2.2.6 Western blotting 
Recombinant protein and brain homogenates of transgenic animals or cell lysates were 
diluted in 5X SDS buffer with β-mercaptoethanol and heated at 95°C for 15 min before 
resolving. 50 ng of recombinant protein or 15 µg of brain lysates or 10 µg of whole cell 
lysate was resolved on 10% or 17% SDS- polyacrylamide gel. Then the SDS gels were 
incubated in 1X transfer buffer for 20 min on an orbital shaker at room temperature. 
Immobilon-P membrane (Millipore) was activated by soaking it in methanol for 1 min 
and then washed in transfer buffer. 3 pieces of wet Whatman filter papers are stacked 
on a transfer apparatus with the activated PVDF membrane, SDS gel and 3 wet 
Whatman filter papers are piled in sequence from bottom to top. The transfer of protein 
from SDS gel to PVDF membrane was initiated by applying 100 mA (1.5 mA per cm2) 
for 2 h. The transfer was confirmed by prestained marker on the membrane. Then the 
membrane was blocked in 5% fat dry milk powder in 1X TBST for 1 h at room 
temperature on an orbital shaker. Later the membrane was incubated in primary 
antibody (1X TBST) at 4°C overnight  on an orbital shaker and then the unbound or 
loosely bound antibody was washed away by washing the membrane with 1X TBST  
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(3 times, 10 min each). The membrane was incubated in HRP labelled secondary 
antibody (1X TBST) at 37°C for 1 h on a rotator and the unbound antibody was washed 
away with 1X TBST buffer (3 times, 10 min each). The membrane was developed using 
ECL reagent and the images were documented using LAS ImageQuant  
(GE Healthcare). 
2.2.2.7 Silver staining 
After resolving the desired protein on SDS gel, the gel was incubated in a fixative 
solution for 15 min followed by cross-linking solution for 30 min or overnight. Then the 
gel was washed with doubly distilled water (3 times, 10 min each). The gel was 
incubated in silver nitrate staining solution for 20 min and then washed with doubly 
distilled water for 30 seconds. Then the gel was incubated in the developing solution 
until the protein was visible on the gel .Then the developing solution was immediately 
discarded and stopping reagent was added to prevent further development of the gel. 
All steps were carried out at room temperature and on an orbital shaker.   
2.2.2.8 Enzyme-linked immunosorbent assay (ELISA) 
96-well plates were coated with 250 ng/well of recombinant tau protein dissolved in 
0.05 M sodium bicarbonate, pH 9.6 as coating buffer and incubated at 4°C overnight. 
Plates were washed with 1X TBST (3 times, 10 min each), followed by blocking with 
5% BSA in TBST for 2 h at room temperature. Primary antibodies (tissue culture 
supernatant) of interest (1:10) diluted in 5% BSA were incubated at 4°C, overnight. 
Plates were washed with 1X TBST (3 times, 10 min each), followed by incubating the 
plates with anti- rat or anti- mouse HRP conjugated secondary antibodies (1:1000) 
diluted in blocking solution, for 1 h at 37°C. . Finally, plates were washed with 1XTBST 
(3 times, 10 min each) and incubated with 100 μl of  
3,3,5,5-tetramethylbenzidine (TMB liquid substrate; SIGMA) for 1 h in darkness. Then 
the reaction was stopped with 100 μl of 2 M HCl. Absorbance was read at 450 nm in 
TECAN spectrofluorimeter (Ascent, Lab systems, Frankfurt). 
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2.2.2.9 Immunolabeling of an antibody 
Monoclonal antibody was concentrated using 3000 MWT amicon filters (Millipore) in 
centrifuge (Eppendorf 5810R) at 2770 rpm, 4°C to achieve the final concentrations of 
50-100 µM. 10X excess molar concentrations of TCEP (tris-(2-carboxyethyl) 
phosphine, Molecular Probes) to antibody was added and incubated on ice for 30 min, 
whereupon 11.85X excess molar concentrations of Alexa 647 dye (ThermoFischer, 
USA) was dissolved in DMSO, added and incubated on ice for 30min. NAP-5 column 
(GE-healthcare, USA) was equilibrated with 10 ml PBS and ~500 µl of the antibody 
mixture was transferred on the column bed and eluted with 1 ml PBS buffer. Protein 
yield (280 nm), dye concentration (650 nm) and labeling efficiency were determined 
using the NanoDrop spectrophotometer (Peqlab ND-1000). Degree of labeling (DOL) 
was calculated using the following equation. 
𝐷𝐷𝐷𝐷𝐷𝐷 = A(dye) 𝑋𝑋 Є (𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝)
𝐴𝐴 280 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 − (𝐴𝐴𝐴𝐴𝐴𝐴𝑝𝑝 𝑋𝑋 𝐶𝐶𝐶𝐶 280) 𝑋𝑋 Є  𝐴𝐴𝐴𝐴𝑝𝑝 
Є IgG protein – 203000; Є A647 dye – 265000; CF 280 (A647) - 0.03. 
The quality of the protein was checked using 10% SDS-PAGE followed by coomassie 
staining. 
2.2.3 Biophysical methods 
2.2.3.1 ThioflavinS (ThS) assay  
ThS dye binds to cross β-sheet containing aggregates which are typical of amyloid 
aggregates. Inhibition of tau aggregation by monoclonal antibodies was monitored in 
presence of ThS dye. 10 µM of tau monomer in BES pH 7.0 with or without 2.5 µM 
heparin (MW 16,000), with or without different concentrations of antibody in presence 
of 40 µM of ThS was prepared for a maximum of 40µl and loaded in 384 well plates 
(black microtiter 384 plate round well, Thermolabsystems, Dreieich), and 
measurements were carried out using Magellan software in a TECAN 
spectrofluorimeter (Ascent, Lab systems, Frankfurt). Kinetics was carried out at 37°C 
for 24 h with measurement intervals of 15 min using excitation wavelength of  
440 nm, an emission wavelength of 521 nm with spectral bandwidths of 2.5 nm for 
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excitation and emission. Samples were prepared in duplicates or triplicates and after 
the measurements, the background fluorescence from ThS alone was subtracted. 
2.2.3.2 Dynamic light scattering (DLS) 
Using the principles of Brownian motion and Doppler shift the size and number of the 
particles in a suspension can be determined by dynamic light scattering (DLS) or  
quasi-elastic light scattering (QUELS). Using this technique the size differences 
between particles (monomers, oligomers or aggregates) can be determined provided 
the size differences are sufficiently large (minimum 5-fold).  After 24 h, 20µl of the 
aggregated sample (with or without antibody) was placed in quartz batch cuvette 
(ZEN2112) and thermally equilibrated at 25°C for 2 min in Zetasizer Nano S (Malvern, 
Herrenberg) instrument fitted with 5-milliwatt helium-neon 633 nm laser at 173° 
measurement angle. Intensity of the scattered particle, their size and numbers were 
obtained as an average of 3 measurements with 20 runs each. The results are 
expressed as volume graph.  
2.2.3.3 Atomic force microscopy (AFM) 
Atomic force microscopy is a powerful microscopy technology for studying samples at 
nanoscale. In AFM, imaging a surface topography by using attractive and repulsive 
interaction forces between a few atoms attached at a tip of a cantilever and a sample 
and these forces are received in photodiode and is proportional to the size of the 
particle. AFM sample preparation and imaging was performed as described earlier 
(Wegmann et al., 2012). In brief, mica discs pasted on a glass slide were freshly 
cleaved using a sticky tape. On these freshly cleaved mica, 1-2 µM of protein sample 
diluted in adsorption buffer (PBS, pH 7.4) was incubated for 10 min followed by 
washing with PBS, pH 7.4 (3-5 times) to remove loosely bound protein on the surface.  
AFM Imaging: AFM imaging was done in oscillation mode for all Tau samples in liquid. 
The cantilever (MSNL10) was inserted in the cantilever holder attached with fluid cell. 
This assembled setup was attached to the AFM head. The laser was aligned on the 
end of the tip and the set up was thermally equilibrated for 10-20 min at room 
temperature. The oscillation of frequency and drive amplitude for oscillation mode 
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imaging was chosen using the inbuilt auto-tuning procedure. The surface was 
approached in an oscillation mode with an amplitude set point of 70% (0.7V) of the 
target amplitude (1V). Once the surface was reached, the minimal contact between the 
sample and cantilever was maintained by altering the amplitude set point manually. 
The images were acquired at a scan rate of 1Hz with the resolution of 512 by 512 
pixels. During the scanning the gains and amplitude set points were altered manually 
often to keep a minimal force between the cantilever and the sample. The images were 
acquired using the JPK Nano Wizard ultra-speed AFM microscope facility at CAESAR. 
The acquired images were processed by the JPK data processing software. 
2.2.3.4 Bio-Layer Interferometry (BLI) 
The BLI (bio-layer interferometry) technology used by BLItz provides real-time data on 
protein interactions. BLI is an analytical technique which measures the binding 
affinities of macromolecules. It is a label-free technology which measures the 
interference patterns caused by the binding of protein to its binding partner, which is 
immobilized on the biosensor surface. Kinetics assay was performed by capturing the 
monoclonal antibodies using anti-mouse IgG Fc capture (AMC) biosensors followed 
by buffer baseline for 30 s. mAb captured sensors were submerged in a sample with 
different tau constructs for 5 min followed by dissociation. The binding sensograms 
were obtained and the binding parameters (on and off rates ka, kd, dissociation 
constant KD) were calculated by local fitting (1:1 Langmuir interaction model) by BLItz 
Pro 1.2 software.  
2.2.4 Cell culture 
2.2.4.1 N2a cells maintenance 
N2a wildtype and inducible cell lines were grown in minimal essential media (Sigma, 
Germany) supplemented with 10% FBS, 5 ml non-essential amino acids (PAA, Austria) 
and 1X penicillin and streptomycin antibiotic (complete media). The cells were grown 
at 37°C in a 5% CO2 incubator. At 80-90% cell confluence they were sub-cultured by 
trypsin digestion as follows. Cells grown on T25 flask were washed twice with warm 
PBS and trypsinized with 1 ml of trypsin at 37°C in 5% CO2 incubator for 2-3 min. 4 ml 
of complete media was added to inhibit the trypsin activity and the trypsinized cells 
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were centrifuged at 1250 rpm for 2-3 min at RT. Supernatant was removed and 5 ml 
of complete media was added to the pellet and sub-culture was established in 1:5-1:10 
ratio. The inducible N2a cell lines expressing tau were generated in our lab previously 
(Khlistunova et al., 2006); these cells require antibiotics Geneticin (G418) (300 µg/ml) 
and Hygromycin (100 µg/ml). 
2.2.4.2 N2a cells freezing 
N2a cell freezing media (50% FBS + 30% MEM + 20% DMSO) was prepared and 
sterile filtered using 0.22 µm filter. 90-100% confluent cells in T75 flask were washed 
twice with warm sterile PBS and 3 ml trypsin was added and incubated at 37°C in 5% 
CO2 incubator for 2-3 min. 4 ml of complete media was added to inhibit the trypsin 
activity. Cells were centrifuged at 1250 rpm for 2-3 min at RT to pellet down the cells. 
2-3 ml of freezing media was added to the pellet and the cells were counted using the 
Neubauer chamber. 1X106 cells/cryo vial was prepared and transferred to isopropanol 
container for 24 h at -80°C and then transferred to liquid nitrogen for long-term storage. 
2.2.4.3 N2a cells recovery 
One cryo vial with N2a cells retrieved from liquid nitrogen was thawed and the cells 
were washed twice with 4 ml of warm complete media by centrifugation (1250 rpm, RT, 
3 min) to get rid of DMSO. To the final pellet 5 ml of complete media was added and 
the cells were plated in T25 flask. For inducible N2a cell lines antibiotics G418  
(300 µg/ml) and Hygromycin (100 µg/ml) were added.  
2.2.4.4 Transfection (DNA) for luciferase complementation assay 
Luciferase complementation fragments were generated using plasmid pCBG99 (click 
beetle green). The amino acid sequence of the luciferase complementation fragments 
2-413 for N-terminus (Luc-N) and 395-542 for C-terminus (Luc-C) were amplified by 
PCR. The PCR fragments were cloned into the pTauRDΔK-EGFPN1 (enhanced green 
fluorescent protein) vector by replacing the GFP with Luc-N or Luc-C (see appendix 
for the plasmid map). N2a cells were plated in a T25 flask to achieve uniform 
transfection efficiency. Plasmids pEGFPN1-Luc-N (3.24 µg) and pEGFPN1-Luc-C  
(2.7 µg) were mixed together in reduced-serum opti-MEM medium (1150 µl). 
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Lipofectamine2000 (25 µl) (Invitrogen) was also diluted in opti-MEM medium (1150 µl). 
Both the DNA and lipofectamine were mixed together and incubated at RT for 5 min. 
The cells were washed with warm PBS and the reaction mixture was added on the 
cells and incubated for 2 h at 37°C in 5% CO2 incubator. After 2 h, 4 ml of complete 
medium was added and further incubated for another 2 h. Later the cells were 
trypsinized and all the cells were plated in 96 well plate equally in all wells. 
2.2.4.5 Antibody transfection into cells 
Xfect protein transfection reagent kit (Clontech) was used to deliver the protein of 
interest into the cells. N2a cells were plated in 6 well plate with a density of 3x105 cells 
per well. After 24 h, 15 µl of Xfect transfection reagent was mixed with 85 µl of 
deionized water. In another tube protein of our interest and Xfect transfection buffer 
was made to the final volume of 100 µl. Both the reaction mixtures were pooled and 
the solution was pipetted gently for 10-15 times. Afterwards the solution was incubated 
at RT for 30 min. 400 µl of serum free media was added to the mixture and the whole 
content of 600 µl was added to the cells for 2 h at 37°C in a CO2 incubator. After 2 h, 
1.4 ml of complete media was added on the cells and incubated for 15 h. 
2.2.4.6 Annexin V staining 
Annexin V conjugate was used for detecting phosphatidylserine (PS) exposed on the 
outer plasma membrane, a hallmark of early apoptosis. Annexin V is 35-36 kDa Ca2+ 
dependent phospholipid binding protein. APC (Allophycocyanin) labelled Annexin V 
can identify early stage apoptosis. Inducible N2a cells expressing TauRDΔK were treated 
with desired antibodies and grown for 4 days. Cells were trypsinized and centrifuged, 
supernatant was removed and the cell pellet was suspended in 100 µl of 1X Annexin 
binding buffer and 5 µl of Annexin V dye was added and incubated in dark for 30 min 
at RT. Cells were washed in 1X binding buffer and collected in PBS buffer. Cell 
counting was performed in Gallios Beckman-Coulter Flow Cytometer. 20,000 cells per 
sample were counted to check Annexin V positive cells.  
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2.2.4.7 Thioflavin S staining of N2a cells 
The ThS dye binds to protein aggregates containing cross β-sheet structures, a 
hallmark of amyloid aggregates. Inducible N2a cells expressing TauRDΔK were treated 
with desired antibodies and 0.0001% of ThS dye and grown for 4 days at 37°C in a 
CO2 incubator. Cells were trypsinized and centrifuged, supernatant was removed and 
the cell pellet was resuspended in PBS buffer. Using Gallios Beckman-Coulter Flow 
Cytometer 20,000 cells per sample were counted to check for ThS positive cells.  
2.2.4.8 Flow cytometry-Fluorescence Activated Cell Sorting (FACS) 
FACS is a laser based technology used to count cells by suspending cells in a stream 
of fluid and passing them by an electronic laser based detection system. Blue laser 
(488 nm) was used to excite ThS (excitation-440 nm; emission 521 nm) and red laser 
(683 nm) was used to excite Annexin V (excitation-633 nm; emission 665 nm). 
Trypsinized cells were centrifuged and collected into 1 ml PBS and then measured on 
the FITC channel/APC channel with a flow-rate of 30 μl/min. The instrument (Beckman) 
was allowed to count a maximum of 20,000 events. Counting was carried out at RT. 
2.2.4.9 Staining lysosomes 
N2a cells were grown to maximum confluence. Old medium was removed from the 
cells and diluted with 75 nM Lyso tracker red DND 99 (L7528, Molecular Probes) dye 
resolved in fresh complete warm medium and added to the cells and incubated for  
2 h at 37°C in 5% CO2 incubator. After 2 h the medium was removed and the cells 
were fixed using 4% sucrose and 3.7% formaldehyde in PBS for 30 min at 37°C and 
then cells were washed thrice with PBS buffer at RT. If required co-staining of other 
antibodies can be performed using immunocytochemistry protocol.  
2.2.4.10 Immunocytochemistry  
N2a cells were treated with desired antibodies at different concentrations for 24 h. 
Afterwards the cells were fixed in solution with 4% sucrose and 3.7% formaldehyde in 
PBS for 30 min at 37°C and then cells were washed thrice with PBS buffer. Later the 
cells were permeabilized and blocked using 5% BSA and 0.5% TritonX-100 in PBS for 
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6 min at room temperature and then washed thrice with PBS buffer. Primary antibody 
was diluted in blocking solution and incubated on cells at 4°C for overnight on a shaker. 
Unbound or loosely bound antibodies were washed thrice using PBS. Secondary 
antibody was diluted in blocking solution and incubated on cells for 1 h at 37°C. Cells 
were washed thrice with PBS. 10 µg/ml of DAPI in PBS buffer was incubated for  
10 min at RT followed by washing with PBS. Finally, cells were mounted on a glass 
slide using poly mount solution and dried at 4°C.  
2.2.4.11 Confocal microscopy 
Image acquisition of cells and tissue sections was carried out using Zeiss LSM 700 
confocal microscope. Images were captured at 20X, 40X and 60X magnification. 
Image quantification was carried out using the software Zen blue edition (2012, Zeiss). 
For image acquisition gain values of positive control were considered as reference in 
order to minimize the overexposure of the samples. 
2.2.4.12 IVIS imaging  
In vivo imaging system (IVIS, Spectrum; Caliper Life Sciences, Germany) allows high-
sensitivity in vivo imaging of fluorescence and bioluminescence. The Click beetle fly 
luciferase gene was split in to two parts i.e. split luciferase N-terminal and split 
luciferase C-terminal and each split luciferase construct was cloned on to the  
C-terminal of the TauRDΔK gene. The co-expression of these two plasmids leads to the 
translation of two tau-protein constructs fused to two complementary parts of the 
reporter protein Luciferase. If the tau protein molecules interact with each other the 
complementary fragments of the separated reporter Luciferase complement form 
active Luciferase which in the presence of the substrate D-Luciferin emits light 
detectable in the IVIS (Caliper Life Sciences, Germany) or another luminometer.  
 
After 15 h of expression in N2a cells 5 µg/ml of D-luciferin was added and incubated 
for 10-20 min prior to the measurement. D-luciferin interacts with Luciferase in the 
cytoplasm in an ATP (Adenosine Triphosphate) dependent reaction and emits light 
Luciferin + O2 + ATP                            Oxyluciferin + CO2 + AMP + diphosphate + Light 
Luciferase 
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which can be recorded. Bioluminescence images are acquired using IVIS according to 
the manufacturer's protocol.  
2.2.4.13 Brain tissue homogenization 
Animals were sacrificed by cervical dislocation and the whole brains were removed. 
Half of the brain (hemisphere) was frozen in liquid nitrogen for biochemistry. Other half 
of the brain was used for brain homogenate preparation, the brain sample was thawed 
on ice and 800 µl of 1x lysis buffer was added and the tissue was minced using a 1 ml 
syringe attached with 18G needle and later with 24G needle. The sample was 
incubated on ice for 30 min. Later the sample was resuspended with a pipette and was 
centrifuged at 14,000 rpm at room temperature. The supernatant was collected and 
the protein concentration was estimated using BCA method. 
2.2.4.14 Immunohistochemistry (IHC) 
Animals were sacrificed by cervical dislocation and the whole brain was removed. Half 
of the brain (hemisphere) was fixed using 3.7% formaldehyde in PBS for 24 h at 4°C, 
followed by sucrose gradient (10%, 20% and 30%) fixation for 24 h in each gradient at 
4°C. Brain was sliced (free floating sections) in to 50 µm equal sections from top to 
bottom using a vibratome (Leica VT 1200S, Germany) and the sections were collected 
and stored in PBS. Antigen epitope retrieval was carried out by adding 10 mM sodium 
citrate buffer (hot (80°C) to the sections and incubating the sections for 30 min at 80°C. 
Sections were washed with PBS (3 times, 10 min each). For permeabilization sections 
were incubated in 0.1% Triton-X 100 for 1 h at RT on an orbital shaker. Sections were 
washed with PBS (3 times, 10 min each).Sections were incubated in blocking solution 
(0.3% Triton-X 100, 2% horse serum in PBS) for 2 h at RT on a shaker. Primary 
antibody was diluted in blocking solution and incubated at 4°C overnight on a shaker. 
Sections were washed with 0.1% Triton-X100 in PBS (3 times, 10 min each) on a 
shaker. Secondary antibody was diluted in blocking solution and incubated on sections 
for 2 h at 37°C (shaker). Sections were washed with 0.1% Triton-X100 in PBS (3 times, 
10 min each) on a shaker. 10 µg/ml of DAPI in PBS buffer was incubated for 10 min at 
room temperature followed by washing with PBS. Finally, sections were mounted using 
poly-mount solution and the coverslips were dried at 4°C.  
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2.2.5 Statistics 
All experimental data were normalized with buffer controls. The statistics was done 
using Graph Pad (Prism) software. The significance of differences was analyzed by 
one- way ANOVA test with Tukey´s post hoc test. In all the experiments the confidence 
interval was set at 95%. Hence a p value < 0.05 was considered to be statistically 
significant.
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3 Results 
In Alzheimer disease models, the pathology induced by tau aggregation was previously 
analyzed in cell models  (Khlistunova et al., 2006, Wang et al., 2007, Kaniyappan et 
al., 2017, Pickhardt et al., 2017) and in transgenic mouse models (Mocanu et al., 2008, 
Van der Jeugd et al., 2012, Decker et al., 2016). Tau aggregation inhibitors can block 
the aggregation by binding to tau (Pickhardt et al., 2007a, Yanamandra et al., 2013) or 
by blocking inducers of tau aggregation (Shelton et al., 2017). Recent reports suggest 
that passive immunization of mice with anti-tau antibodies can ameliorate tau 
pathology in tau transgenic animals (Yanamandra et al., 2013, Dai et al., 2015), but 
the underlying mechanisms and targets remain a matter of debate. The studies 
presented here demonstrate the targets and modes of activity of anti-tau monoclonal 
antibodies which are raised against toxic oligomers. 
3.1 Purified TauRDΔK oligomers as antigens for generating monoclonal 
antibodies 
The antigens for generating monoclonal antibodies were the purified oligomers of the 
mutant tau repeat domain with the deletion of lysine 280 (TauRDΔK). TauRDΔK readily 
forms aggregates and has the propensity to form β-sheet structure, hence its 
description as a pro-aggregant form of tau (Figure 3.1 A). TauRDΔK oligomers were 
prepared and purified as described previously (Kaniyappan et al., 2017). Briefly, 50 µM 
recombinant TauRDΔK (Mr~13.5 kDa) was diluted in TBS pH 9.0 and incubated at 37°C 
for 30 min for aggregation. The aggregated sample was cross-linked using 0.01% 
glutaraldehyde (GA) for 10 min at 37°C to stabilize the oligomers. The cross-linked 
sample was purified using a BFF 16/10 hydrophobic column. Figure 3.1 B represents 
the silver stained SDS gel with TauRDΔK samples before and after purification. TauRDΔK 
aggregated and cross-linked before purification (lane 1) shows different species of 
TauRDΔK monomers and oligomers with some higher aggregates (see the gel pockets). 
The oligomers formed are mostly low-n oligomers ranging from dimer, trimer, and 
tetramer to some higher order oligomers. Cross-linked aggregates after purification 
(lane 3) have predominantly low-n oligomers with no monomers or higher aggregates 
(fibrils). The oligomers are separated from monomers due to their hydrophobicity. The 
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purified oligomers are predominantly low-n oligomers (dimers to hexamers) which were 
confirmed by AFM imaging.  
The AFM-height image (Figure 3.1 C) reveals that the oligomers are globular in shape 
and are mostly in the range of 4-6 nm which corresponds to the height of dimers to 
hexamers of TauRDΔK. These purified and well characterized oligomers of TauRDΔK were 
used as an antigen for generating the monoclonal antibodies. 
3.2 Generation of monoclonal antibodies 
The monoclonal antibodies were generated by our collaborator (Dr. Elizabeth Kremmer 
and Dr. Regina Feederle) at Helmholtz Center, Munich. We received tissue culture 
supernatants and purified antibodies of the clones that recognize the oligomers for 
further characterization.  
3.3 Analysis of specificity of monoclonal antibodies 
Monoclonal antibodies raised against purified oligomers of TauRDΔK were screened for 
their specificity to potential targets. Aggregation of tau from non-toxic monomers to 
fibrils, implies various targets (protein species, conformations) for aggregation 
inhibitors and dis-aggregators (Howlett, 2001). In order to explore the specificity of 
antibodies to monomers or aggregation intermediates or fibrils, different constructs 
(repeat domain/full length) and different species (monomers, oligomers and fibrils) of 
tau were employed. Immunoassay methods like dot blots, western blots and ELISA 
were used to explore the affinity of antibodies in denaturing and non-denaturing 
conditions. 
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Figure 3.1: Purified oligomers of TauRDΔK as antigen for monoclonal antibodies. 
Purified low-n oligomers of TauRDΔK were used as antigen to inject in mice and rat to generate different 
monoclonal antibodies specific to low-n oligomers of tau. A) The representational image of full length 
human tau (2N4R, 441aa) with two N-terminal inserts 1N and 2N (khaki box), two proline rich regions 
P1 and P2 (pink box) and repeat region with four repeats R1, R2, R3 and R4 (green box). Repeat 
region R2 and R3 comprises two hexapeptide motifs (red box) which promote aggregation of tau. The 
repeat region (K18) of tau (aa 244-372) with deletion of lysine at position 280 (ΔK280) increases the 
propensity of tau to form β-sheet containing aggregates. B) Silver staining of 17% SDS-PAGE with 
TauRDΔK oligomers. TauRDΔK was aggregated to form low-n oligomers for 30min at 37°C in TBS pH 9.0 
and later cross-linked using 0.01% GA for 10min at 37°C. Unpurified oligomers run on the gel contain 
monomers which run at 13.5 kDa and low-n oligomers ranging from dimers to tetramers and some 
higher order oligomers (lane, 1). Oligomers were separated from monomers using Butyl FF 16/10 
hydrophobic interaction chromatography column. The purified fractions on SDS gel confirm that 
oligomers were separated from monomers (lane, 3). C) AFM height image of purified oligomers of 
TauRDΔK shows that most of the protein is comprised of low-n oligomers with heights ranging from 
~4nm-6nm corresponding to 3-5 stacked monomers of tau and some higher aggregates with heights 
of >10nm. Abbreviation: TauRDΔK, repeat region of tau with ΔK280 mutation; Oligo, unpurified 
oligomers; Oligo*, purified oligomers; kDa, kilo Dalton; SDS-PAGE, sodium dodecylsulfate- poly 
acrylamide gel electrophoresis; GA, glutaraldehyde. 
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3.4 Specificity of antibodies against tau oligomers 
Prior to in vivo testing, antibodies were extensively characterized in vitro and in cellular 
models to select potential candidates for in vivo studies. The dot blot method was 
employed for initial testing as this method did not use any chemical denaturing agents. 
It retains the antigen on the membrane in its natural conformation. To determine the 
specificity of the monoclonal antibodies, different mutants of tau and different species 
of tau were used (Figure 3.2). The polyclonal K9JA pan-tau antibody (detecting all 
constructs and assembly forms of tau) was used as an internal control to demonstrate 
that the protein was loaded in all lanes (row 1a-j). Antibodies 6H3, 8E7, 26G1  
(rows 6-8) detected most forms of tau with varying affinities. Antibodies 26G1, 28D4, 
29E2, 32E7 (rows 8-11) showed strong preferences for prefibrillar-aggregates of tau 
irrespective of mutation and domain structure (rows 8-11, columns c, g, i). Antibodies 
2G9 and 6H1 had strong affinity for high molecular weight aggregates of TauRDΔK  
(rows 3, 5, column d, pink boxes) as they did not detect purified low-n tau oligomers. 
Antibody 6B5 (row 4, columns d, i) showed high affinity for aggregates of RD/FL tau 
with ΔK280 mutation. Antibody 2B10 was the most specific, it showed high affinity only 
for TauRDΔK purified oligomers (green box, row 2c). The anti-aggregant variants of tau 
(mutation ΔK280-2P) were recognized by antibodies 6H3, 8E7, and 26G1 (rows 6j, 7e, 
8j). Overall, the dot blot results showed that although all antibodies were raised against 
the same antigen (purified oligomers of TauRDΔK) they showed different specificities 
and affinities for different tau constructs.  
The same antibodies yielded different results when they were probed to antigens under 
denaturing conditions in western blots. The 2B10 antibody did not discriminate 
between any tau mutants and detected all forms of tau in denaturing conditions. The 
antibody 2B10 showed affinity for all forms of recombinant FL and RD tau  
(Figure 3.3 A, lanes 1-8) but it did not detect RD or FL tau in brain lysates. Non-specific 
binding was observed in case of brain lysates (Figure 3.3 A, lanes 10-12). Antibody 
6H1 detected all forms of recombinant tau (Figure 3.3 B, lanes 1-8) and also hTau40ΔK 
and mouse tau in brain lysates (Figure 3.3 B, lanes 10-12). These results suggest that 
under denaturing condition these antibodies detect tau without any specificity. 
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Figure 3.2: Analysis of specificity of anti-tau oligomer antibodies by dot blot. 
Anti-tau oligomer monoclonal antibodies exhibit differential abilities to bind to different tau species or 
constructs. Different constructs of recombinant tau protein (TauRDΔK, hTau40Wt and hTau40ΔK) were 
prepared in vitro in monomeric form. TauRDΔK oligomers (purified and unpurified) were prepared by 
incubating monomers at 37°C for 30 min in TBS pH 9.0 and cross-linked with 0.01%GA for 10 min. 
Aggregates of tau were prepared by incubating the tau monomers in the presence of heparin at 37°C 
for 120 h in BES pH 7.0. 50 ng/well of protein was loaded on PVDF membrane and immunoblotted 
with different anti-tau oligomer monoclonal antibodies (3 µg/blot). Row 1a-j: A representative blot 
(pan-tau polyclonal antibody K9JA) acts as a positive control which detects all tau constructs and 
assembly forms. By contrast, different monoclonal antibodies have different specificities and affinities 
to different constructs and assembly forms of tau. Row 2: Antibody 2B10 shows high specificity for 
the oligomer-enriched sample (blot 2c, green box) whereas some antibodies such as 2G9 (blot 3d), 
and 6H1 (blot 5d) show high affinity to aggregates (pink box) of the repeat domain (RD) of tau with 
the ΔK mutation. Antibody 6B5 (row 4) shows strong affinity towards aggregates of repeat domain or 
full length tau with the ΔK mutation (blots 4d, 4i). Rows 6-11: Further representative dot blots of 
different monoclonal antibodies are shown to illustrate the differential ability of antibodies to detect 
different tau species or constructs. Note the enhanced reaction with oligomer-enriched species of tau 
RD (rows 6-11, column c) and with aggregates of full-length tau (rows 6-11, column i),  Abbreviations: 
TauRDΔK, human tau repeat domain with pro-aggregant mutation ΔK280; hTau40WT, full length human 
wild type tau; hTau40ΔK, full length human tau with pro-aggregant mutation ΔK280; Mono, monomer; 
Oligo, uncross-linked and unpurified oligomers; Oligo*, cross-linked and purified oligomers; Agg, 
Aggregates; 2P- human tau with anti-aggregant mutation ΔK280/2P; RD, repeat domain; FL, full 
length. 
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Figure 3.3: Interactions of monoclonal antibodies in denaturing western blots. 
Recombinant protein (50 ng/well, lanes 1-8) and brain lysates (15 µg/well, lanes 10-12) were loaded 
on the SDS gels and immunoblotted with anti-tau oligomer monoclonal antibodies (tissue culture 
supernatant; 1:10 dilution). Antibody 2B10 (A) and 6H1 (B) detects all forms of RD and FL recombinant 
tau. Lanes: (1) TauRD-WT monomer, Mr~13.8 kDa, (2) TauRDΔK monomer, (3) TauRDΔK oligomers  
~60-80 kDa, (4) TauRDΔK fibrils broken down into oligomers (Mr ~35-80 kDa), (5) anti-aggregant 
TauRDΔK-2P (monomers and oligomers ~70 kDa), (6-8) monomers from hTau40WT, hTau40ΔK,  
hTau40ΔK-2P, ~65 kDa. Antibody 2B10 (A, lanes 10-12) shows non-specific interactions in transgenic 
brain lysates expressing RD or FL tau. By comparison, 6H1 antibody detected the FL human tau  
(B, lane 12) and mouse tau (B, lane 10, 11, 12) in transgenic brain lysates. Abbreviations: Mono, 
monomers; Oligo*, cross-linked and purified oligomers; TauRDΔK, human tau repeat domain with  
pro-aggregant mutation ΔK280; hTau40ΔK, full length human tau with pro-aggregant mutation ΔK280; 
hTau40WT, full length human wild type tau; 2P- human tau with anti-aggregant mutation ΔK280/2P; RD, 
repeat domain; FL, full length. 
The affinity and specificity of monoclonal antibodies to their antigen was also analyzed 
by indirect ELISA. Different mutant and different forms of Tau proteins were coated on 
the plates and probed with the monoclonal antibodies. The 2B10 and 6B5 antibodies 
showed strong affinity to both unpurified and purified oligomers of TauRDΔK but not to 
monomers or fibrils (Figure 3.4 A and C). The 6H1 antibody showed equal affinity for 
all forms of TauRDΔK (mono, oligo and fibrils) and did not show preferences to any of 
them (Figure 3.4 B). Surprisingly, the 8E7 antibody showed stronger affinity for purified 
oligomers of tau than for unpurified oligomers (Figure 3.4 D) which could be due to the 
accessibility of the potential binding sites for 8E7 antibody in cross-linked oligomers. 
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Figure 3.4: Analysis of specificity of mAb’s by indirect ELISA. 
Indirect-ELISA was used to analyse the affinity of mAb’s to its antigen. 250 ng/well of antigen was 
coated on the 96well plates and incubated with primary anti-tau oligomer antibodies (tissue culture 
supernatant (1:10 dilution)) overnight at 4°C and then suitable HRPO-labelled secondary antibodies 
were used and detected with the ELISA kit with absorbance at 450 nm. A) The representative graphs 
of the antibodies show that 2B10 antibody has high affinity for TauRDΔK oligomers (bars 2, 3) compared 
to monomer and fibrils (bars 1 and 4) (n=3; one-way ANOVA with Tukey’s post hoc test; F (3, 12) = 
24.51; ****P<0.0001 and ***P<0.001). B) Antibody 6H1 binds to all forms of TauRDΔK. It does not 
discriminate oligomers (bars 2, 3) from monomers and fibrils (bars 1 and 4) (n=3; one-way ANOVA 
with Tukey’s post hoc test; F (3, 12) = 1.469; ****P=0.2725). C) Antibody 6B5 shows high affinity to 
oligomers (bars 2, 3) compared to monomer and fibrils (bars 1 and 4) similar to 2B10 antibody (n=3; 
one-way ANOVA with Tukey’s post hoc test; F (3, 12) = 11.06; **P<0.01). D) Antibody 8E7 shows high 
affinity to purified oligomers* (bar 3) compared to un-purified oligomers (bar 2), monomers and fibrils 
(bars 1 and 4) (n=3; one-way ANOVA with Tukey’s post hoc test; F (3, 12) = 418.6; **P<0.0001). 
Abbreviations: mAb, monoclonal antibody; ANOVA, analysis of variance; Mono, monomers; Oligo, 
uncross-linked and unpurified oligomers; Oligo*, cross-linked and purified oligomers; HRPO, 
horseradish peroxidase. 
Summarizing these results (dot blot, western blot and ELISA), it appears that these 
anti-tau oligomer antibodies demonstrate different properties based on the method 
used for analysis. Since the dot blot analysis is based on non-denaturing conditions, 
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we selected the antibodies based on dot blot results. Interestingly, ELISA (another non-
denaturing based condition) supported the dot blot results. 
3.5 Immunocytochemistry and Immunohistochemistry 
We next determined the specificity of antibodies in cell and animal models using the 
immunofluorescence method. Fixed N2a-wt cells and N2a cells expressing TauRDΔK 
were probed with antibodies 2B10 and 6H1. Anti-tau K9JA antibody was used as total 
tau antibody.  2B10 and 6H1 antibodies detected human tau with high specificity in 
N2a-TauRDΔK cells (Figure 3.5 A, images 4, 7). Positive control antibody K9JA detected 
tau strongly in N2a-TauRDΔK cells (Figure 3.5 A, images 5, 8) and antibodies 2B10 and 
6H1 showed co-localization (yellow) with the K9JA antibody (Figure 3.5 A, images 6, 
9) which confirmed the specificity of 2B10 and 6H1 to human tau in cell models. 
Interestingly, 2B10 and 6H1 antibodies appeared also to detect other tau forms with 
no co-localization with K9JA. This suggests that these antibodies have affinities for 
oligomers as well as aggregates. All the antibodies showed little or no background 
fluorescence in N2a-wt cells which do not have human tau but have low amounts of 
mouse tau (Figure 3.5 A, images 1, 2, 3). Figure 3.5 B shows the affinity of 2B10 
antibody in fixed free floating brain slices of control and KT1.K4 (TauRDΔK) mice. 2B10 
antibody detected human tau in KT1.K4 animals with high specificity in the soma and 
in dendritic processes (Figure 3.5 B, images 3 white arrows) of the CA1 and CA3 
regions of the hippocampus (Figure 3.5 B, images 3, 4) without showing any affinity to 
mouse tau expressed in control brains (Figure 3.5 B, images 1, 2). The 
immunofluorescence data suggest that 2B10 antibody shows high affinity for human 
tau in cell and animal models. 
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Figure 3.5: 2B10 antibody is specific to TauRDΔK in immunofluorescence. 
Monoclonal antibodies detected tau with high specificity in cell and animal models. A) 2B10 and 6H1 
antibodies (green) detected tau in N2a cells expressing TauRDΔK (image 4, 7) but with minimal or no 
staining in N2a-wt cells (image 1; the image 1 belongs to 2B10 antibody; since 6H1 antibody also 
shows similar results, it is represented as 2B10/6H1). Pan tau K9JA antibody was used as a total tau 
antibody (image 2, 5, 6) which co-localized with anti-tau oligomer antibodies (image 6, 9). B) Free 
floating mice brain sections probed with 2B10 antibody showed tau staining mostly in the soma and 
some dendritic processes (white arrows) of CA1 and CA3 neurons in the transgenic mouse 
expressing TauRDΔK (image 3, 4). 2B10 antibody did not show any staining in the control brain  
(Image 1, 2) owing to its high specificity to TauRDΔK. 
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3.6  Analysis of affinity of the antibodies by biolayer interferometry (BLItz) 
 
Figure 3.6: Affinity analysis of monoclonal antibodies by BLItz. 
Bio-layer interferometry (BLItz) shows the binding affinities of immobilized monoclonal antibodies 
towards different constructs of human tau (FL/RD) and mouse tau. A) Representational image of 
BLItz sensogram shows the different phases of the assay. The initial phase is the buffer baseline  
(30 s) with the adsorption buffer. The second phase shows immobilization of different antibodies such 
as 2B10 (2677nM), 6H1 (866.7 nM), 6B5 (250.7 nM), 8E7 (72.67 nM) (120 s).  After that the buffer 
baseline is run for 30 s. In the next step different constructs of FL/RD human tau and mouse tau are 
run to determine the association rate constant (ka), dissociation rate constant (kd), and binding 
constant (KD) of each antibody towards human and mouse tau. B) BlItz sensograms of immobilized 
antibodies (2B10, 6H1, 6B5 and 8E7) towards TauRDΔK (green), hT40WT (red) and mTau40 (black). 
The sensograms shows ka and kd values of different tau constructs towards antibodies. KD values are 
calculated from the obtained ka and kd values. Abbreviations: nM, nanomolar; s, seconds; nm, 
nanometre; RD, repeat domain tau; ka, association rate constant; kd, dissociation rate constant; KD, 
dissociation constant/binding affinity.  
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The binding affinities of the antibodies with the different tau constructs were determined 
by biolayer interferometry (BLItz). Figure 3.6 A, shows a typical BLI assay sensogram, 
which involved four essential steps. Buffer equilibration step, immobilization of the 
ligand, association of the analyte (ka) followed by a dissociation step (kd). The 
association (ka) and dissociation (kd) rate constants were calculated by a titration series 
of the antigen run against an immobilized antibody. The data set was analyzed with 
global fitting (1:1 Langmuir interaction model), using Octet software (ForteBio), thereby 
producing a ka, kd, KD. The binding affinity (KD) was calculated by the ratio of the kd/ka. 
Sensograms in Figure 3.6 B showed association of four antibodies (2B10, 6H1, 6B5, 
and 8E7) with human (hT40WT, TauRDΔK) tau and mouse tau (mTau40). 2B10 antibody 
showed similar rate constants for association (ka = 2.02 ×103 Ms-1) and dissociation 
rate (kd =2.68 ×10-2 s-1) (see Table 3.1) to hT40WT and mouse tau which resulted in a 
low dissociation constant (KD = 13.22 µM). This antibody showed moderate binding 
affinity to TauRDΔK (KD = 1.21 µM) with low ka = 2.22 ×104 Ms-1 and kd = 2.69 ×10-2 s-1. 
By contrast, 6H1 antibody showed nano molar (nM) range affinities to all three antigens 
with similar ka (ka = 2.69 ×105 Ms-1) to human tau and low ka for mouse tau. The kd 
value for TauRDΔK was higher compared to the other 2 antigens (human tau and mouse 
tau). Therefore the affinity of the 6H1 towards TauRDΔK (KD = 19.19 nM) was higher 
than to the other 2 antigens (hT40WT - 51.34 nM and mouse tau – 133.2 nM). Antibody  
Sample  2B10  (2677 nM) 
6H1  
(866 nM) 
6B5 
 (250 nM) 
8E7 
(72 nM) 
 
hTau40WT 
KD (M) 13.22 µM 51.34 nM 138.1 nM 2.10 nM 
ka (Ms-1) 2.02 × 103 2.69 × 105 1.17 × 105 7.34 × 106 
kd (s-1) 2.68 × 10-2 1.38 × 10-2 1.62 × 10-2 1.54 × 10-2 
 
TauRDΔK 
KD (M) 1.21 µM 19.19 nM 4.92 nM 0.59 nM 
ka (Ms-1) 2.22 × 104 1.55 × 105 1.37 × 105 7.21 × 106 
kd (s-1) 2.69 × 10-2 2.97 × 10-3 6.89 × 10-4 4.29 × 10-3 
 
mTau 
KD (M) 11.87 µM 133.2 nM 184.5 nM 1.11 nM 
ka (Ms-1) 1.57 × 103 5.72 × 104 3.19 × 104 8.87 × 106 
kd (s-1) 1.86 × 10-2 7.62 × 10-3 1.49 × 10-4 1.00 × 10-3 
Table 3.1: Affinity analysis of antibodies by BLItz. 
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6B5 also showed nano molar range affinities to all FL/RD human tau constructs and 
mouse tau but with highest affinity for TauRDΔK. 8E7 antibody had the strongest binding 
affinities to hTau40WT (KD = 2.10 nM), TauRDΔK (KD = 0.59 nM) and mTau40  
(KD = 1.11 nM). 8E7 antibody showed similar high ka and kd values to the three 
antigens. Of all the tested antibodies, the 2B10 antibody showed the weakest affinities 
with micro molar (µM) range binding affinity. The other antibodies showed nano molar 
(nM) range binding affinities to human and mouse tau. 
3.7 Antibodies eluted at acidic pH have enhanced activity 
 
Figure 3.7: Activity of antibodies depends on pH of elution buffer. 
10 µM of recombinant hTauP301L (2N4R) was incubated in the presence of heparin (2.5 µM)  and  
10 µM of mAb in BES pH 7.0 and the aggregation kinetics were monitored for 24 h at 37°C in the 
presence of the dye ThS (40 µM). Anti-tau antibody 2B10 eluted at acidic pH of 2.7 (green curve) had 
higher activity than the antibody eluted at lower acidic pH of 4.0 (yellow curve) compared to the control 
i.e. hTauP301L with heparin and without antibody (blue curve). As the pH of the elution buffer of the 
antibodies increased from more acidic (pH 2.7) to less acidic (pH 4.0) the antibodies lose their ability 
to block the aggregation of tau (green, orange, pink and yellow curves). Abbreviations: hTauP301L, full 
length human tau with mutation of proline to leucine at the 301 position; Hep, heparin 16000; ThS, 
thioflavin S.  
Different batches of 2B10 antibody showed differences in their ability to inhibit the 
aggregation (data not shown). We assumed that this was due to the differences in 
purification. Moreover it is known that low-pH elution buffer-exposed IgG antibodies 
acquire enhanced activity (Djoumerska-Alexieva et al., 2010). Therefore, 2B10 
antibody purification was carried out at different acidic environments. The purified 
antibody was tested for its ability to block the tau-tau interaction leading to aggregation. 
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Usually 10 µM of antibody with 10 µM of hTauP301L were incubated to test aggregation 
in the presence of ThS and heparin in BES buffer pH 7.0. As expected, the antibodies 
eluted at different pH showed differences in their activity to block aggregation of tau. 
Figure 3.7 showed that hTauP301L+heparin forms ThS positive aggregates (blue curve) 
whereas, an antibody (eluted at pH 4.0) did not inhibit the aggregation of the tau (yellow 
curve).  In contrast, tau in the presence of antibody eluted at pH 2.7 decreased the 
aggregation of tau significantly (green curve). Antibody eluted at pH 3.0 and 3.2 
displayed significant reduction in the aggregation of tau (brown and pink curves 
respectively). Taken together, we conclude that the higher the acidity (i.e. lower pH) of 
the elution buffer of the antibody is, the higher is the activity of the antibody to inhibit 
tau aggregation. 
3.8 Anti-tau oligomer antibodies block the aggregation of tau in vitro 
Several studies reported the close association of the NFT burden and the degree of 
cognitive impairment in Alzheimer disease (Arriagada et al., 1992, Spillantini and 
Goedert, 2013, Braak and Braak, 1991a). As the process begins at least 20 years 
before any clinical manifestations of Alzheimer disease are detected, targeting tau 
aggregation offers a rational approach to treatment and prevention (Nelson et al., 
2012). The use of monoclonal antibodies is one such approach for inhibiting tau 
aggregation.  Identification of tau aggregation inhibitors depends primarily on assays 
conducted in vitro with recombinant human tau proteins. A primary assay which detects 
aggregation products includes ThS dye-based fluorescence (Kumar et al., 2014).  
These assays depend on exogenous polyanionic inducers such as heparin or RNA 
(Goedert et al., 1996, Kampers et al., 1996) to increase the rate and extent of tau 
aggregation. In the absence of inhibitors like antibodies, tau aggregates into PHF’s, 
whereas in the presence of antibodies tau aggregation can be inhibited. Therefore we 
utilized the ThS assay to test the abilities of our antibodies to inhibit tau-aggregation. 
10 µM of tau (aggregation prone mutants of tau - TauRDΔK and hTauP301L) and 10 µM 
of antibody were incubated at 37°C for 24 h in the presence of 40µM ThS and 2.5 µM 
heparin16000 along with appropriate controls. Kinetics of ThS were measured for  
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Figure 3.8: Anti-tau oligomer monoclonal antibodies block tau aggregation in vitro. 
Monoclonal antibodies block the aggregation of tau into ThS positive aggregates. 10 µM of TauRDΔK 
or hTauP301L was incubated in the presence of heparin (2.5 µM) and 10 µM of different monoclonal 
antibodies in BES pH 7.0 and the aggregation was monitored for 24 h at 37°C in the presence of ThS. 
A) Antibodies 2B10 (green curve) and (B) 6H1 (pink curve) effectively blocked the aggregation of 
TauRDΔK and hTauP301L compared to their respective controls (blue curves). In the presence of 
antibodies the protein was restricted mostly to its monomeric form. C) Quantification of the ability of 
different mAb’s blocking the aggregation of hTauP301L was summarized in the table. The number 
denotes the percentage of aggregation inhibition by the respective antibodies. Antibodies like 2B10 
and 6H1 (green) are very robust in blocking the aggregation of tau by 90 & 89% respectively. Some 
antibodies like 8E7, 26G1, 28D4 and 29E2 block the aggregation by >50% whereas the antibodies 
like 2G9, 2H9, 6B5, 6H3 and 32E7 partially block the aggregation by <50%. Abbreviations: ThS, 
thioflavin S; Hep, heparin; h, hours. A.U., arbitrary units. 
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every 15 min. In the presence of heparin tau aggregated and reached saturation in  
3 h for TauRDΔK (blue curves in Figure 3.8 A) and 15 h in hTauP301L (blue curve in Figure 
3.8 B) compared to tau monomers in the absence of heparin (red curves in Figure 3.8 
A, B) which did not show any increase in ThS fluorescence even after 24 h. Antibodies 
2B10 (green curve) and 6H1 (pink curve) inhibited the formation of ThS positive 
aggregates of tau dramatically (~90%).  
Quantification of the aggregation inhibition of hTauP301L (tau:antibodies = 1:1 molar 
ratio concentration) showed that some antibodies like 2B10 and 6H1 were able to 
inhibit the aggregation of tau up to 90%, whereas some antibodies like 8E7, 26G1, 
28D4 and 29E2 were able to inhibit aggregation up to>50% (Figure 3.8 B). Antibodies 
2H9, 6B5 inhibited aggregation poorly (<20%).  
This result confirms that anti-tau oligomer antibodies are able to inhibit the tau 
aggregation with different efficiencies. 
3.9 Antibodies reduce tau aggregation by blocking the low-n oligomeric state 
Fluorescence-based aggregation assays allow high throughput screening, so they are 
well suited for primary screens, whereas DLS and AFM microscopy approaches 
provide detailed insights regarding quantity, composition and morphology of 
aggregation species (Wegmann et al., 2012). The size of the tau species in the 
presence of antibodies after 24 h of aggregation in the presence of heparin at 37°C 
was measured by the DLS method. Figure 3.9 A shows the average hydrodynamic 
radius (RH) of hTauP301L aggregates (blue curve) as ~60-100 nm in diameter, whereas 
the monomer (red curve) shows RH ~2-5 nm. The RH of aggregates was >20 fold higher 
than RH of monomers. This represents the presence of high molecular weight 
aggregates or fibrils in the hTauP301L+heparin sample (blue curve). In the presence of 
antibody 2B10 (green curve) and 6H1 (pink curve) the average RH was ~10 nm and  
25 nm diameter respectively. Thus, the average RH values of antibody treated samples 
corresponds to the low-n and high-n oligomers of tau. From the above observation, it 
is evident that antibody 2B10 binds to low-n oligomers (~2-5 monomers) and prevents 
the tau aggregation thereafter. Similarly 6H1 antibody binds to low-n and high-n  
(>10 mers) oligomers and prevents further aggregation.  
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Figure 3.9: Structural forms of tau in the presence of monoclonal antibodies. 
10 µM of hTauP301L was incubated in the presence of heparin (2.5 µM) with or without different 
antibodies (10 µM) in BES pH 7.0 for 24 h at 37°C. A) The hydrodynamic radius (measured by 
dynamic light scattering) of hTauP301L in the presence of antibodies 2B10 (green) and 6H1 (pink) was 
mostly in the range of low-n oligomers i.e. <20nm compared to that of the control (blue), which was 
in the range of 10-200nm. B) Height and amplitude images of atomic force microscopy revealed that 
antibody treated hTauP301L was mostly in the form of oligomers (2B10 and 6H1). Antibodies like 6B5 
and 8E7 showed few aggregated forms of tau.Abbreviation: d. nm, diameter in nanometer; nm, 
nanometer; mV, milli volt. 
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Structural analysis is necessary to determine the nature of aggregates. We performed 
AFM analysis that revealed the morphology of the tau in the presence and absence of 
the antibodies. Figure 3.9 B shows the height and amplitude images of the tau. In the 
absence of antibodies, hTauP301L formed lengthy PHF’s which are clearly visible in 
height and amplitude images. The height of the hTauP301L PHF’s were broadly in the 
range of 10-18 nm. In the presence of the antibody 2B10, tau aggregation was 
restricted up to low-n oligomers that were characterized by their globular shape with 
an average height of 2-3 nm that corresponded to the dimer-tetramer of tau oligomers 
(Kaniyappan et al., 2017). In the presence of the antibody 6H1, tau was restricted to 
low-n oligomers and some bigger aggregates. In both cases, no tau filaments were 
observed. Antibodies 6B5 and 8E7 also inhibited the tau aggregation, but to a lesser 
extent. In the presence of 6B5 and 8E7 antibodies, short tau-filaments were observed 
on mica by AFM. 
Taken together, we conclude that anti-tau oligomer monoclonal antibodies are active 
in inhibiting the aggregation of tau in vitro and halt the growth at the oligomer state.  
3.10 Concentration dependent activity of antibodies to block tau aggregation 
For any inhibitor (antibody) that binds reversibly to a single site on a target molecule 
(i.e., a 1:1 binding stoichiometry), one expects that binding, hence inhibition, will be 
saturable leaving no traces of active target (aggregation-competent tau). To determine 
the concentration of antibody required to diminish the aggregation of tau protein, 
different stoichiometric concentrations of antibodies were employed to inhibit tau 
aggregation. Based on the previous observations (Figure 3.8 C) regarding the ability 
of antibodies to inhibit the tau aggregation in ThS fluorescence kinetics, low 
concentrations of 2B10, 6H1, 8E7 and high concentrations of 6B5 antibodies were 
tested against 10 µM of hTauP301L. Figure 3.10 A shows hTauP301L+heparin aggregated 
effectively (blue curve). Tau protein in the presence of antibody at 1:1 ratio inhibited 
tau aggregation by 3-4 ~fold (green curve). Reducing the concentration of antibody 
(Tau:Antibody = 1:0.5 (orange curve) and 1:0.25 (pink curve)), showed the aggregation 
inhibition in a concentration dependent manner. In Figure 3.10 B 6H1 antibody at  
10 µM (pink curve) and 5 µM (orange curve) concentrations decreased the aggregation 
propensity of tau by ~3-4 fold. At 2.5 µM (green curve) concentration also showed a  
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Figure 3.10: Antibody dependent inhibition of tau aggregation. 
Inhibition of aggregation of tau by anti-tau antibodies is dependent on the molar ratio of antibody to tau 
concentration. 10 µM of hTauP301L was incubated with different concentrations of antibody in the 
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presence of heparin. A) 2B10 antibody at 10 µM (green curve) was able to inhibit tau aggregation 
better than 5 µM (orange curve) and 2.5 µM (pink curve) B) 6H1 antibody at 10 µM (pink curve) and  
5 µM (orange curve) concentrations showed similar activity at inhibiting tau aggregation but at lower 
concentrations of 2.5 µM (green curve) it showed decreased ability to inhibit tau aggregation. C) 8E7 
antibody showed concentration dependent inhibition of tau aggregation. 10 µM (green curve) of 
antibody showed better inhibition compared to 5 µM (orange curve) and 2.5 µM (pink curve). D) 6B5 
antibody did not show any significant difference in inhibiting tau aggregation even after increasing the 
antibody concentration from 10 µM (pink curve) to 20 µM (orange curve). Abbreviation: ThS, thioflavin 
S; A.U., arbitrary unit; Hep, heparin 16,000. 
decrease in tau aggregation, however the effect was smaller. Similarly in  
Figure 3.10 C the antibody 8E7 showed concentration dependent inhibitory activity. As 
the concentration of antibody increased from 2.5 µM (pink curve) to 5 µM (orange 
curve) and 10 µM (green curve), there was an increase in the antibody's ability to inhibit 
tau aggregation.  
Figure 3.10 D, 10 µM (pink curve) of 6B5 antibody did not inhibit the aggregation 
whereas increasing the concentration up to 2 fold i.e. 20 µM (orange curve) had a 
noticeable effect. The results demonstrate that antibodies 2B10 and 6H1 are able to 
inhibit tau aggregation at approximately equal stoichiometric ratios of tau to antibody 
whereas other antibodies such as 6B5 were not able to inhibit the aggregation even at 
higher concentration. 
3.11 Intracellular delivery of antibodies has no effect on aggregation of tau and 
early apoptosis in N2a cells expressing TauRDΔK 
Inhibition of tau aggregation within the neurons is one of the major targets in the field 
of tauopathies. Since the experimental results of tau aggregation inhibition by 
monoclonal antibodies in vitro was successful we further subjected them to test in cell 
culture models. N2a cells with inducible expression of TauRDΔK forms fibrous 
aggregates (Khlistunova et al., 2006) and the population of cells with aggregates can 
be measured by the dye ThS. ThS is cell permeable when added to the cell culture 
medium and its fluorescence can be recorded in live cells using flow cytometry 
(Pickhardt et al., 2017).  
Since tau aggregation takes place intracellularly, the antibodies have to be delivered 
into the cells to combat tau aggregation. Antibodies can be internalized via bulk 
endocytosis or via receptor Fc mediated endocytosis (Congdon et al., 2013). However, 
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for experimental purposes we used the Xfect protein transfection reagent to deliver 
antibodies directly into the cells. The representative image Figure 3.11A shows that 
anti-tau antibodies were delivered into the N2a-cells expressing TauRDΔK using Xfect 
transfection reagent. After 2 h N2a cells were incubated with 1 µg/ml of doxycycline 
and 0.0005% ThS for 96 h and ThS positive cells were measured using flow cytometry. 
ThS fluorescence was detected in the green-channel (y-axis) and diffracted light 
around the cell (intensity proportional to cell diameter) is measured as forward scatter 
(x-axis).  In Figure 3.11B, antibodies 2B10 (3.40%), 6H1 (3.73%) and 6B5 (3.48%) 
treated cells at 15 µg/well (166.6 nM) concentration did not show any significant 
differences in ThS+ cell population compared to the control (3.38%). This indicates 
that these antibodies were inefficient at blocking the aggregation of tau in the cells. By 
contrast, cells treated with antibody 8E7 showed a slight (4.02%) increase in ThS+ cell 
population compared to control, suggesting some enhancement of aggregation. None 
of the other antibodies reduced ThS positive cells. Taken together we conclude that 
antibodies at this concentration are ineffective in inhibiting the aggregation in cells. 
Annexin V (AnnV) is an indicator of early steps in apoptosis, which can be measured 
by incubating the cell with fluorescent AnnV (AnnV-APC for red fluorescence). 
Allophycocyanin (APC) is an intensely bright phycobili protein that exhibits far-red 
fluorescence. AnnV binds to the cells that display phosphatidylserine (PS) on the cell 
surface during the event of early apoptosis. AnnV positive cells can be measured in 
flow cytometer by using APC conjugated AnnV. N2a cells over-expressing TauRDΔK in 
the presence of doxycycline show moderate cell death due to expression and 
aggregation of TauRDΔK. Therefore we further investigated whether the antibodies can 
rescue the cells from toxic effects induced by TauRDΔK. Anti-tau antibodies were 
delivered into the cells using Xfect transfection reagent as before and AnnV positive 
cells were measured after the antibody treatment (96h in cells). In Figure 3.11 C, 
antibodies 2B10 (1.02%), 6H1 (1.22%), 6B5 (1.64%) and 8E7 (1.50%) treated cells did 
not show any significant differences in AnnV population compared to the control 
(1.18%). None of the antibodies have shown any decrease in the early apoptosis 
caused by TauRDΔK. Overall, the intracellular delivery of anti-tau antibodies did not  
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Figure 3.11: Intracellular delivery of antibodies has no effect on tau aggregation. 
15 µg/well (25 µg/ml) of anti-tau oligomer antibodies were delivered into the cells (N2a-TauRDΔK) using 
Xfect reagent to combat the aggregation of tau in cells (as judged by decrease in ThS+ cells) and 
rescue the cells from apoptosis (by decreasing APC-Annexin V staining- a pre-apoptotic  marker).       
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A) Diagram of the Xfect protein transfection procedure: antibodies encapsulated in Xfect reagent (pink) 
were incubated with N2a-TauRDΔK for 2 h. Later N2a cells were incubated with 1 µg/ml of doxycycline 
and 0.0005% ThS for 96 h (stained with Annexin V after 96 h). ThS/Annexin V positive cells were 
counted using flow cytometry and plotted in a graph of forward scatter (cell diameter,  
x-axis) versus fluorescence (ThS/Annexin V fluorescence intensity, y-axis).  B) Forward scatter plot 
(cell volume, x-axis) versus “green” channel (ThS fluorescence, y-axis). Area II (Q2) represents the 
ThS positive cell population. Dox induced cells showed 3.38% ThS positive cells. None of the 
antibodies have reduced ThS positive cell population. C) Forward scatter plot (cell volume, x-axis) 
versus “red” channel (APC Annexin V fluorescence, y-axis). Area II (Q2) represents the AnnV positive 
cell population. Dox induced cells showed 1.18% AnnV positive cells. None of the antibodies rescued 
the cells from pathological effects caused by TauRDΔK. Abbreviations: AnnV, Annexin V; ThS, thioflavin 
S; Q2, quadrant 2. 
show any significant effects in blocking the tau aggregation or decreasing the early 
apoptosis caused by the pro-aggregant tau. 
3.12 Tau split-luciferase protein-fragment complementation assay 
Data from experiments described above suggests that antibodies were effective at 
blocking tau aggregation in vitro but not in N2a cells expressing TauRDΔK, as judged by 
ThS fluorescence assay (reflecting the end products of aggregation/high molecular 
weight aggregates). Therefore antibodies were further tested to explore whether they 
can inhibit the initial stages of tau aggregation, i.e., dimerization or oligomerization. For 
this purpose, we adopted a well-characterized macromolecular interaction platform  
i.e. split-luciferase complementation assay (Villalobos et al., 2010). TauRDΔK was fused 
with either N-terminal (Luc-N) or C-terminal (Luc-C) fragments of click beetle green 
luciferase. N2a wildtype cells were used to interrogate the interaction of TauRDΔK 
monomers which was monitored by luciferase protein fragment complementation and 
analyzed by bioluminescence imaging of live cells (Wang et al., 2017). After 15 h of 
co-transfection of tau constructs (TauRDΔK-Luc-N+ TauRDΔK-Luc-C) in N2a cells, the 
dimerization of tau can be measured by bioluminescence of luciferin (Figure 3.12, first 
well and bar 1). But in case of cells transfected either with TauRDΔK-Luc-N or  
TauRDΔK-Luc-C did not show any bioluminescence signal which shows that without the 
presence of two complement luciferase constructs there is no bioluminescence signal 
detected (Figure 3.12, bar 2, 3). To rule out the possibility of a bioluminescence signal 
without tau, we co-transfected the N2a cells with Luc-N and Luc-C constructs without 
any tau. In this case there was no luminescence signal detectable (Figure 3.12, well 4 
and bar 4). These results confirm that bioluminescence based on tau-split luciferase 
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protein-fragment complementation assay is an ideal assay to detect initial a key early 
step in tau aggregation. 
 
Figure 3.12: Tau-luciferase protein-fragment complementation assay. 
Click-beetle green luciferase gene was split in to two complementary units containing N-terminal  
(Luc-N) and C-terminal (Luc-C) parts. These two complementary fragments are fused to the  
C-terminal end of TauRDΔK. The diagram at top shows the luciferase bioluminescence in N2a cells 
expressing tau constructs (TauRDΔK-Luc-N+ TauRDΔK-Luc-C) (bar 1). No bioluminescence was 
observed in cells expressing controls (TauRDΔK-Luc-N, bar 2), (TauRDΔK-Luc-C, bar 3), (Luc-N + Luc-
C, bar 4). TauRDΔK, pro-aggregant repeat domain tau; Luc-N, luciferase N-terminal part; Luc-C, 
Luciferase C-terminal part.  (n=3; one-way ANOVA with Tukey’s post hoc test; F (3, 8) = 98.08; 
****P=<0.0001). 
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3.13 Antibodies inhibit tau dimerization in tau-luciferase protein-fragment 
complementation assay 
 
Figure 3.13: Effect of antibodies on dimerization of tau monitored by tau-
luciferase protein-fragment complementation assay. 
A) Graphical representation showing tau-luciferase protein-fragment complementation assay. N2a 
cells were co-transfected with TauRDΔK-Luc-N and TauRDΔK-Luc-C. Affinity of tau molecules 
(dimerization or oligomerization) will lead to complementation of both split luciferase fragments 
resulting in measurable bioluminescence signal. Bioluminescence signal indicates tau dimerization 
and hence aggregation. Antibody treatment blocks tau dimerization and decreases the 
bioluminescence signal intensity. B) N2a cells expressing these constructs were treated with 100 
µg/ml of various antibodies. Representational image of 96 well plate showing ability of antibodies 
in blocking tau aggregation was recorded by capturing the bioluminescence intensity. Histogram 
was plotted based on the recorded bioluminescence intensity values. 2B10 antibody (bar 4, red 
oval) shows significant decrease in bioluminescence signal compared to untreated N2a cells (n=3; 
one-way ANOVA with Tukey’s post hoc test; F (10, 22) = 5.755; ***P=0.0003. 
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Monoclonal antibodies are further tested to explore their ability to attenuate the tau 
aggregation process at the stage of dimerization. N2a cells were co-transfected with 
tau-luciferase constructs (TauRDΔK-Luc-N + TauRDΔK-Luc-C) and after 5-8 h of DNA-
transfection, antibodies were incubated for 15 h in the extracellular medium (without 
any transfection reagent) followed by imaging (Figure 3.13 A). Figure 3.13 B shows 
that treatment with antibodies has shown significant differences in bioluminescence 
signal which relates to changes in tau dimerization in cells. 2B10 antibody (bar 4, red 
oval) dramatically decreased tau dimerization, as it has shown only ~10% 
bioluminescence intensity (lane 4) compared to the untreated (bar 1; lane 1) and 
control non-specific FLAG antibody treated cells (bar 11; lane 11). Some antibodies 
like 8E7 (bar 5; lane 5), 6B5 (bar 6; lane 6) and 2G9 (bar 8; lane 8) showed ~60% 
bioluminescence signal compared to control but the result was not statistically 
significant. By contrast, antibodies like 6H1 (bar 2; lane 2), 11D10 (bar 3; lane 3), 2H9 
(bar 7; lane 7), 29E2 (bar 9; lane 9), and 26G1 (bar 10; lane 10) did not show any 
significant difference compared with controls.  From these results, we conclude that 
antibody 2B10 efficiently blocks the dimerization/oligomerization of tau. 
3.14 Antibody 2B10 blocks the dimerization in a concentration dependent 
manner 
Antibody 2B10 was further tested to search for the lowest concentration of the antibody 
which reproduces the inhibition of dimerization or oligomerization in cells (Figure 3.13). 
N2a cells transfected with tau-luciferase constructs were incubated (extracellularly) 
with various concentrations of 2B10 antibody ranging from 6.25-100 µg/ml (Figure 
3.14). Concentrations of the 2B10 antibody as low as 6.25 µg/ml (41 nM) (bar 2;  
lane 2) were able decrease the bioluminescence intensity to ~75% compared to the 
untreated (bar1; lane 1) and control antibody treated (bar 7; lane 7) samples. Higher 
amounts of 2B10 antibody like 12.5 µg/ml (83 nM) (bar 3; lane 3), 25 µg/ml (166 nM) 
(bar 4; lane 4) and 50 µg/ml (333 nM) (bar 5; lane 5) were able to decrease the 
bioluminescence intensity to ~60%. 2B10 antibody showed significant decrease in the 
bioluminescence intensity to ~40% at the highest concentration of 100 µg/ml (666 nM) 
(bar 6; lane 6). 2B10 antibody decreased the bioluminescence in a concentration-
dependent manner. 
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Figure 3.14: 2B10 antibody inhibits the dimerization of tau. 
A)  N2a cells were co-transfected with TauRDΔK-Luc-N and TauRDΔK-Luc-C constructs. Cells were 
treated with various concentrations (6.25, 12.5, 25, 50, 100 µg/ml) of 2B10 and control antibodies for 
15h. Representative images illustrating the decrease in bioluminescence intensity are shown on top 
and quantified in the histogram. 100 µg/ml (bar 7) of 2B10 antibody showed significant decrease in 
bioluminescence compared with the controls (bars 1, 2). By contrast, 100 µg/ml (bar 7) of control FLAG 
antibody did not show any significant difference with the controls (bars 1, 2) (n=3; one-way ANOVA 
with Tukey’s post hoc test; F (7, 16) = 4.481; **P=0.0062).  
3.15 Uptake of antibodies by N2a cells 
From the results described above, it is evident that antibodies which are applied 
extracellularly are able to inhibit the intracellular oligomerization of tau (fragment 
complementation assay). But the question remains how these extracellular antibodies 
are acting on intracellular tau aggregation? We therefore explored whether the 
antibodies enter the cells, using published procedures (Shamir et al., 2016). Antibody 
uptake assay was done with the A647 fluorophore tagged 2B10 antibody and non-
specific FLAG antibodies. Different concentrations of antibodies ranging from               
10-60 µg/ml (66-400 nM) were added to N2a wildtype cells and N2a cells expressing  
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Figure 3.15: Internalization of tau antibodies. 
Uptake of antibodies by cells was monitored by immunofluorescence. N2a- wt cells or N2a cells 
expressing TauRDΔK were treated extracellularly with 10-60 µg/ml of Alexa647 tagged 2B10 (red) and 
non-specific FLAG (red) antibodies for 24 h. Cells were then fixed for immunocytochemistry. Alexa 
tagged 2B10 antibody showed uptake both in N2a-wt (images 1, 4, 7) and N2a-TauRDΔK (images 2, 5, 
8) cells. Non-specific FLAG antibodies were also taken up by N2a-TauRDΔK cells (images 3, 6). 
Magnified images of 2B10 antibody (images 9, 10) showed localization of antibody as punctate 
structures (white arrows) in the cells. Abbreviations: Wt, wild type; TauRDΔK, pro-aggregant repeat 
domain tau; DOX, doxycycline.   
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TauRDΔK in the extracellular medium for 24 h, then cells were fixed to observe the 
antibody uptake. After 24 h, uptake of 2B10 antibody was observed in both cells types 
(N2a-wt, N2a- TauRDΔK) irrespective of the presence or absence of the tau inside the 
cell. Antibody uptake was observed at all concentrations (10, 40 and 60 µg/ml of 2B10 
antibody) in both the N2a-wt cells (Figure 3.15, images 1, 4, 7) and N2a- TauRDΔK cells 
(Figure 3.15, images 2, 5, 8). Surprisingly, non-specific FLAG antibody was also taken 
up by N2a- TauRDΔK cells (Figure 3.15, images 3, 6). We also noticed at higher 
magnification that the antibodies in cells were not distributed homogeneously in the 
cytoplasm, but rather were localized as punctate dots (Figure 3.15, image 9, 10- 
arrowhead). 
3.16 Localization of internalized antibodies in lysosomes of N2a cells 
 
Figure 3.16: Localization of antibodies in lysosomes. 
60 µg/ml of A647 labelled 2B10 (red) and FLAG (red) antibodies were applied extracellularly for 24 h 
with 75 nM of Lysotracker dye (green) on N2a-TauRDΔK cells induced with doxycycline. Lysotracker dye 
stained the lysosomes (image 1, 4). 2B10 and FLAG antibodies were taken up by cells and localized 
as punctate structures (images 2, 5). These antibodies showed co-localization (yellow) with lysosomes 
(images 3, 6). Abbreviations: TauRDΔK, pro-aggregant repeat domain tau; DOX, doxycycline. 
The above results (Figure 3.15, image 9, 10) suggest that the extracellular antibodies 
are internalized by N2a cells and are localized in punctate structures. In order to 
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understand the specific nature of these punctate structures in which antibodies are 
sorted we stained the cells with fluorescent dyes which label and track acidic 
organelles in living cells (LysotrackerRed DND 99). This dye is cell permeable and 
binds to lysosomes. 24 h of incubation of fluorophore labelled 2B10 (red) and non-
specific FLAG (red) antibodies on N2a-TauRDΔK cells showed a significant uptake of 
antibodies by cells and the antibody was compartmentalized in to punctate structures 
(Figure 3.16,  images 2, 5). Lysotracker dye (green) stained the acidic organells with 
low pH in the cytoplasm (Figure 3.16, images 1, 4). Antibodies 2B10 and FLAG showed 
co-localization (yellow) with the lysotracker dye (Figure 3.16, images 3, 6) which 
confirms that the tau specific antibody 2B10 and non-specific antibody FLAG were 
internalized by the cells and were sorted to the lysosomes by an unknown mechanism. 
3.17 Antibodies promote tau entry to lysosomes for its clearance 
The antibodies added extracellularly were internalized by the cells and are sorted to 
lysosomes (Figure 3.16), however it is unknown whether the antibodies in lysosomes 
are bound to tau or antibodies promote sorting of tau to lysosomes. To test this we 
incubated N2a-TauRDΔK cells (doxycycline, 48 h) with lysotracker dye (green)  and 
fluorophore labelled 2B10 (red) or FLAG (red) antibodies (extracellularly) for 24 h 
followed by cell fixation and probing with K9JA antibody (blue). Lysotracker dye stained 
the lysosomes (green) (Figure 3.17, images 1, 5). Antibodies 2B10 (red) and FLAG 
(red) were taken up by the cells and compartmentalized as punctate structures (Figure 
3.17, images 2, 6). K9JA antibody (blue) detected TauRDΔK in N2a cells (Figure 3.17, 
images 3, 7). N2a TauRDΔK cells treated with 2B10 antibody showed clear  
co-localization (white) with lysotracker dye and pan tau antibody K9JA (Figure 3.17, 
image 4, white arrows) whereas cells treated with control FLAG antibody cells did not 
show co-localization with the pan tau antibody (Figure 3.17, image 8). It is evident that 
tau was compartmentalized in 2B10 antibody treated cells (Figure 3.17, image 3) but 
in FLAG antibody treated cells tau was distributed all over the cell (Figure 3.17, image 
7). This result shows that 2B10 antibody recruits the tau to lysosomes presumably for 
its clearance. 
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Figure 3.17: Antibodies promote tau clearance via lysosomes 
60 µg/ml of Alexa647 labelled 2B10 (red) or FLAG (red) antibodies were applied extracellularly for  
24 h with 75 nM of Lysotracker dye (green) on N2a-TauRDΔK cells induced with doxycycline. Cells were 
fixed and probed with K9JA antibody (blue) which detected TauRDΔK (image 3, 7). Lysotracker dye 
stained lysosomes (images 1, 5). 2B10 and FLAG antibodies were taken up by cells and 
compartmentalized (images 2, 6). 2B10 antibody shows co-localization with tau and lysosomes (image 
4, white arrows) whereas FLAG antibody shows co-localization only with lysosomes but not with tau 
(image 8). Abbreviations: TauRDΔK, pro-aggregant repeat domain tau. 
In conclusion, the monoclonal antibody 2B10 binds specifically to low-n oligomers of 
tau (dot blot, ELISA, IC and IHC) with weak affinity (BLI). Antibody 2B10 blocks the 
aggregation of tau invitro (ThS, DLS, and AFM) but fails to do so in N2a cells 
expressing TauRDΔK (flow cytometry-ThS). Interestingly, 2B10 antibody added 
extracellularly is able to block the dimerization of tau in an antibody concentration 
dependent manner (split luciferase complement assay). Moreover, extracellularly 
added antibody enters the cells, binds to cytosolic tau (TauRDΔK) and recruits tau 
(presumably toxic oligomers) to lysosomes for degradation.
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4 Discussion 
4.1 Amyloid-β and tau in AD 
Extracellular amyloid plaques comprising amyloid beta peptides and intracellular 
neurofibrillary tangles composed of tau in brain tissue represent the two major 
pathological hallmarks of AD (Fu et al., 2018). Therefore most therapeutic approaches 
have focussed on the reduction of these aggregates, either directly by inhibiting their 
formation, or indirectly by modulating the pathways that lead to aggregate deposition. 
Aβ-targeted approaches were initially (early 1990's) more favored because genetic 
evidence pointed to a causal role of APP cleavage leading to Aβ accumulation in 
familial AD (Hardy and Selkoe, 2002). Under normal physiological conditions, the 
transmembrane protein APP is cleaved by α and γ-secretases. During disease 
condition, improper cleavage of APP by "β secretase" releases Aβ peptides that 
aggregate into filaments in the extracellular matrix and cause synaptic degeneration.  
Thus attempts were made to inhibit β- or γ-secretases or to enhance α-secretases to 
lower the production of amyloid beta. These attempts have been discontinued for lack 
of efficacy or toxic side effects (Hampel et al., 2015). Other drugs were designed to 
inhibit Aβ aggregates to improve memory in transgenic mice. However, these 
approaches have not generated disease-modifying drugs so far, even though animal 
models showed promising results (Cummings et al., 2018).  
As an alternative, the focus shifted to tau protein and its aggregates, particularly since 
mutations in the tau gene were recognized to cause different types of 
neurodegenerative tauopathies closely related to AD (e.g. frontotemporal dementia, 
Pick disease (Lee et al., 2001, Orr et al., 2017). Unlike APP and Aβ, tau is a highly 
soluble cytosolic protein which primarily binds to microtubules and stabilizes them in 
neuronal axons, thus enabling axonal transport or neurite outgrowth (Mandelkow and 
Mandelkow, 2012). Under pathological conditions, tau becomes post-translationally 
modified (e.g. by phosphorylation, proteolysis, acetylation, glycosylation, 
ubiquitinylation), and the corresponding enzymatic pathways served as entry points for 
drug developments (Holtzman et al., 2016). Other approaches included the lowering 
of tau in neurons (by drugs or antisense oligonucleotides), or interference with the 
spreading of tau pathology between brain regions (DeVos et al., 2018). As in the case 
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of Aβ, these approaches have not yet generated disease-modifying drugs for humans, 
in spite of promising results with animal models and in clinical trials up to phase II 
(Medina, 2018). 
4.2 Immunotherapy for AD 
An alternative treatment strategy is immunotherapy. The rationale for this approach is 
that antibodies against aggregating proteins (generated by passive or active 
immunization) can scavenge their targets and deliver them for destruction, for example 
in microglia or in lysosomes of neurons (Funk et al., 2015, Krishnamurthy et al., 2011). 
However, thus far Aβ targeted immunotherapy was not successful, and studies had to 
be halted because of inflammation and other side effects (Honig et al., 2018). Moreover 
Aβ targeted immunotherapy had low or no impact on tau pathology (Boche et al., 2010, 
Nelson et al., 2012, Congdon and Sigurdsson, 2018). Currently several tau-targeted 
immunotherapy studies (both active and passive immunotherapy) are underway. In 
animal models they led to reduction in tau aggregation, phosphorylation and cognitive 
decline in transgenic mice (Castillo-Carranza et al., 2014b, Castillo-Carranza et al., 
2014a, Zilka et al., 2012, Kontsekova et al., 2014, Sigurdsson, 2014, 
Sankaranarayanan et al., 2015, Yanamandra et al., 2013).  
Some of these studies targeted tau protein in general, i.e. all isoforms or assembly 
states (Yanamandra et al., 2013). The main advantage of focusing on total tau was 
that a larger pool of tau can be targeted. However, there was concern about potential 
toxicity associated with clearance of physiologically functional tau protein, and about 
the lack of distinction between diverse modified forms of tau (fragments, 
phosphorylation states etc.) (Pedersen and Sigurdsson, 2015). Alternatively other 
approaches targeted sites in the tau molecule involved in aggregation, or early forms 
of assembly (oligomers) considered to be the most toxic species. Examples are (1) 
antibody DC8E8 against an epitope in the repeat domain which prevents aggregation 
of tau (Kontsekova et al., 2014), (2) antibody TOMA against tau oligomers which 
prevents tau induced toxicity (Castillo-Carranza et al., 2014b). 
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4.3 Characterization of anti-tau low-n oligomeric antibodies 
Our earlier study had shown that low-n oligomers of tau (prepared in a highly pure 
fashion, see below) do not affect cell viability as such. This was in contrast to other 
reports describing pronounced cytotoxicity of oligomer preparations as observed by 
MTT and LDH assays (Flach et al., 2012, Lasagna-Reeves et al., 2011). However, our 
low-n oligomers caused severe synaptotoxicity (Kaniyappan et al., 2017). These 
observations were consistent with early stages of AD pathology where synapses 
become impaired long before neurons decay (Yoshiyama et al., 2007, Conforti et al., 
2007, Van der Jeugd et al., 2012). Since synapses are key regulators of learning and 
memory, we decided to target the species that destroys the synapses and therefore 
raised monoclonal antibodies against low-n oligomers of tau.  
The antigen consisted predominantly of low-n oligomers with sizes ranging from dimers 
to hexamers, roughly globular in shape and purified by a hydrophobic interaction 
chromatography (Figure 3.1). Monoclonal antibodies (mAb’s) raised against these tau 
oligomers were analyzed by biophysical, biochemical and cell biological methods. 
Based on the results from the first characterization of the monoclonal antibodies (tissue 
culture supernatants), we selected the clones that strongly detected tau oligomers and 
aggregates. Antibodies were then tested for their specificity against monomers and 
aggregates (low-n oligomers or fibrils) of wildtype and mutant (ΔK, ΔK-2P) tau (repeat 
domain and full-length). We observed that in dot blot analysis, only the 2B10 antibody 
was specific to purified low-n oligomers of TauRDΔK (Figure 3.2). Other antibodies such 
as 6H1, 2G9 detected both oligomers and aggregates of TauRDΔK.  Antibodies 26G1, 
28D4, 29E2, 32E7 showed strong preferences for prefibrillar-aggregates of tau 
irrespective of mutation and domain structure (Figure 3.2). However the results were 
different when western blotting methods were applied. All mAb’s detected all forms of 
recombinant tau proteins in western blots (Figure 3.3). The discrepancy was due to the 
fact that dot blots kept the protein in a native conformation whereas western blotting 
required denaturation by SDS in the sample buffer. This confirmed that some of the 
antibodies were conformation dependent and recognized tau only under specific 
conditions. These results are reminiscent of the outcomes of experiments with 
monoclonal antibodies specific for Aβ aggregates (Hatami et al., 2014). ELISA analysis 
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confirmed that 2B10 has higher affinity for TauRDΔK oligomers than for monomers 
(Figure 3.4). Immunocytochemistry and immunohistochemistry data revealed that 
antibody 2B10 detects tau protein only in the pro-aggregant tau repeat domain in a 
cellular model of tauopathy and in transgenic mice (Figure 3.5). Since the 2B10 
antibody provides similar results in dot blots and ELISA we consider antibody 2B10 to 
be specific for low-n oligomers of TauRDΔK. We also determined the affinity of the 
antibodies using biolayer interferometry analysis (BLI). The 2B10 antibody specific for 
low-n oligomers of TauRDΔK had the lowest affinity to tau compared to other antibodies.  
Affinity analysis was performed using monomers, as aggregated tau failed to 
immobilize on the chip. This could explain the low affinity for 2B10 antibody (Table 3.1).  
If an antibody would target a toxic or aggregation prone conformation of tau it would 
be a promising asset for a therapeutical intervention in AD and other tauopathies. From 
the preliminary antibody characterization we concluded that several antibodies have a 
conformational epitope, which can be characterized further to use as a therapeutic 
antibody. Earlier monoclonal antibodies were directly tested on tau transgenic animals. 
This type of approach will restrict the researcher to explore off targets and on targets 
of the antibodies in the animals. However, the mechanism of reduction of tau 
aggregation by antibodies is not understood in transgenic mice (Yanamandra et al., 
2013, Castillo-Carranza et al., 2014b). It would therefore be advisable to perform a 
systematic approach to characterize the antibody before entering animal studies. For 
this reason we performed in vitro tau aggregation inhibition assays with tau constructs 
K19, K18 (3-repeat, 4-repeat domain respectively, data not shown), TauRDΔK and 
hTauP301L protein in the presence of heparin and antibodies. This revealed that several 
antibodies inhibit tau aggregation dramatically. More specifically, antibodies 2B10 and 
6H1 strongly (~90%) inhibited the aggregation (Figure 3.8) even at a 1:1 (antibody:tau) 
molar ratio. Similar studies were performed with the antibodies raised against amyloid 
beta peptides (Solomon et al., 1996, Liu et al., 2004). In their conditions aggregation 
of amyloid beta was inhibited either only at a 4:1 (antibody:amyloid beta) molar ratio 
(Solomon et al., 1996) or at 20 µM equimolar concentrations (Liu et al., 2004).  Such 
in vitro studies on inhibition of tau aggregation were not reported prior to our study. 
Therefore we conclude that some of our antibodies at 1:1 (antibody:tau) molar ratio 
inhibit tau aggregation strongly and could be used as potential therapeutic antibodies.  
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In our case, different batches of antibodies from the same clone displayed differences 
in their biological activity (tau aggregation inhibition). It is known that IgG antibodies 
exposed to low-pH elution buffer acquire enhanced activity (Djoumerska-Alexieva et 
al., 2010). Therefore we explored a different purification strategy especially by varying 
the pH of the elution buffer. Indeed, a low pH of the elution buffer (HCl, pH-2.7) yielded 
a substantial increase (~70%) in their biological activity (inhibiting hTauP301L 
aggregation) compared to antibodies eluted at pH-4.0 (Figure 3.7).  
We next characterized the tau aggregates that were formed in the presence of 
antibodies after 24 h by DLS and AFM. These techniques are commonly used to 
characterize protein assemblies in solution (Liu et al., 2004). Dynamic light scattering 
yielded an average hydrodynamic radius of aggregates (formed in the absence of 
antibody) as RH~60-100 nm (equivalent to ~240-400 molecules of hTauP301L). By 
comparison, aggregates formed in presence of antibody 2B10 or 6H1 resulted in 
substantially smaller RH values of ~10nm and 25 nm, respectively. (equivalent to low-
n oligomers).  AFM revealed that in the presence of antibodies the tau protein did not 
form filamentous aggregates. In presence of antibody 2B10 the aggregates had sizes 
of 2-3 nm, equivalent to trimers and tetramers, in the case of antibody 6H1 the sizes 
(2-15 nm) were in the range of dimers up to ~20mers. This means that antibody 2B10 
bound to low-n oligomers, antibody 6H1 to high-n oligomers, and both antibodies 
inhibited tau protein aggregation. Antibody 6B5 did not inhibit tau aggregation 
significantly in vitro, even at higher concentration (1:2 = tau:antibody ratio) (Figure 
3.10). By contrast, antibodies 2B10, 6H1 and 8E7 retained their inhibitory activity even 
at low concentrations (1:0.5 and 0.25 = tau:antibody ratio), making them suitable for 
further translational studies (Figure 3.10).  
Tau is an intracellular protein which aggregates inside the neurons. Abnormal tau 
inside cells can cause microtubule disruption, transport inhibition and dysregulation of 
signaling or degradation pathways (Stamer et al., 2002, Wang and Mandelkow, 2016). 
One of the major questions in the field of tauopathies is the nature of the toxic species 
of tau and their mechanism of toxicity. Several studies suggested that pre-fibrillar forms 
or tau oligomers are the major toxic species (Lasagna-Reeves et al., 2010, Flach et 
al., 2012, Kaniyappan et al., 2017, Yoshiyama et al., 2007, Van der Jeugd et al., 2012, 
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Haass and Selkoe, 2007). One would expect that clearance of cytosolic tau from cells 
by therapeutic antibodies (active or passive immunotherapy) can only be achieved 
when the antibodies enter the cells at the required concentration and inhibit the tau 
aggregation or neutralize the activity of the toxic tau conformation.  
On the other hand a small fraction of tau is also found extracellularly and is thought to 
enable the spreading of tau pathology from cell to cell (Figure 4.1) (Fuster-Matanzo et 
al., 2018, Gibbons et al., 2018). In support of this view, tau is also present at nanomolar 
concentrations in the ISF (Yamada et al., 2011). Therefore it is necessary to inhibit the 
intracellular and extracellular tau to prevent the spreading of tau pathology to other 
brain regions which in turn decrease the overall tau pathology in AD patients. This can 
be achieved by immunotherapy, where an antibody can bind intra or extracellularly to 
pathological tau to degrade it.  
For these reasons tau-immunotherapy gained considerable interest in AD research. 
Several recent studies suggested that intravenous or intraperitoneal injection of tau 
specific antibodies like PHF6, PHF13 (Sankaranarayanan et al., 2015), pSer413, 
pSer396 specific antibodies (Umeda et al., 2015), TOMA antibody against tau 
oligomers (Castillo-Carranza et al., 2014b), N-terminal tau specific antibodies (Dai et 
al., 2015) and human tau specific antibody HJ8.5 (Yanamandra et al., 2013) into 
transgenic animals showed improvement in memory and reduction in intracellular tau 
pathology, especially tau aggregation.  
We therefore investigated whether a specific low-n tau oligomer antibody can inhibit 
the formation of ThS positive cells in an inducible N2a cell model expressing TauRDΔK. 
Extracellular application of the antibodies to N2a cells did not reduce the number of 
ThS positive cells (data not shown). Although different modes (receptor dependent and 
independent) of antibody entry into the cells (SHSY5Y cells and primary neurons) to 
combat intracellular tau pathology had been reported (Congdon et al., 2013, Shamir et 
al., 2016), in our case it appears that the cells did not take up the antibody at the 
required concentration to reduce tau aggregation. We therefore delivered the 
antibodies directly into the cells before the expression of tau was induced, using the 
Xfect transfection reagent. We used 25 µg/ml of antibody to inhibit intracellular tau 
aggregation. Despite such huge concentration, intracellularly delivered antibodies 
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failed to inhibit the tau aggregation (ThS positive cells) in the N2a cell model of 
tauopathy (Figure 3.11). A possible explanation is that the concentration of antibodies 
applied (extra and intracellularly) was very low (167 nM) compared to the high 
concentration (~95 µM) of the tau expressed in N2a cells which was recently reported 
(Pickhardt et al., 2017).  
An important aspect of antibody mediated improvement in tau pathology is neutralizing 
the effects of the toxic tau conformation. Studies performed so far tried to explore the 
antibodies ability to neutralize tau toxicity by incubating the cells with tau-antibody 
complex (tau pre-incubated with antibody) extracellularly and perform toxicity assay 
(MTT) (Lasagna-Reeves et al., 2012). In our case we addressed the toxicity of 
intracellular tau oligomers, using the N2a cell model expressing TauRDΔK. As reported 
previously, the cell death observed in this model is due to the oligomers (Pickhardt et 
al., 2017) whose effect could be presumably eliminated by an antibody specific to tau-
oligomers. Therefore we exposed the N2a cells to antibodies and tested by FACS 
whether this reduced the fraction of Annexin V-labeled cells (a marker of incipient 
apoptosis); however, the treatment had no effect (Figure 3.11).  
There are several reasons possible for these observations on antibody 2B10.  
1) There was insufficient uptake of 2B10 antibody into the N2a cells (expressing  
~95 µM of TauRDΔK (Pickhardt et al., 2017)). The in vitro data show that antibody 2B10 
inhibits tau aggregation at equimolar concentration, but such a high concentration  
(100 µM) of antibody could not be reached in the cell culture system. 
2) The antibody was present in the cell for 96 h. During this time it could have been 
degraded by the cell system (Press et al., 1989). 
3) Selection of the assay: In N2a cells, the ThS dye robustly labels filamentous tau 
aggregates assembled with β-structure, but incipient forms of aggregation (oligomers) 
are not labeled reliably. Therefore reduction of oligomers by antibodies might not have 
been detectable. This would require a more sensitive assay where the initial stages of 
tau aggregation (oligomerization) can be monitored.  
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In order to achieve this we developed a tau-split luciferase complementation assay 
(Villalobos et al., 2010) to monitor the oligomerization of TauRDΔK. This assay monitors 
the early changes that occur during tau dimerization using the interaction of N- or  
C-terminal luciferase fragments fused to tau molecules, respectively, which can be 
visualized by the bioluminescence of luciferin (Wegmann et al., 2016). We  
co-expressed TauRDΔK-Luc-N and TauRDΔK-Luc-C plasmids in N2a cells and applied 
antibodies extracellularly for 15h. Interestingly, antibody 2B10 (specific for low-n 
oligomers) inhibited the tau dimerization completely in a concentration dependent 
manner (Figure 3.14), whereas others had no effect (Figure 3.13). The results were 
intriguing, considering that the antibody with lowest affinity when applied extracellularly 
inhibited the tau-dimerization better than antibodies with higher affinity. Analogous 
observations were made by others (Congdon et al., 2016). Thus the mode of activity 
of antibodies applied extracellularly to inhibit the dimerization of tau inside the cells 
requires further investigation.  
4.4 Entry of antibodies into cells 
We hypothesized that antibody 2B10 must have been internalized by the N2a cells. 
There are contradictory evidences about internalization of antibodies by neurons and 
the mechanism of entry (Yanamandra et al., 2013, Funk et al., 2015, Congdon et al., 
2013). We therefore investigated whether our antibodies are internalized by neurons 
using fluorescent labelling. Alexa 647-tagged 2B10 antibody could be shown to enter 
both N2a wild type cells and transgenic N2a-TauRDΔK cells in a concentration 
dependent manner. All cells were able to take the antibody up but to different degrees 
(Figure 3.15). Surprisingly, we observed that the cells took up all antibodies tested 
including the control antibodies (secondary antibody, FLAG non-specific antibody). We 
also observed that the antibody (2B10) uptake by N2a cells was not dependent on the 
concentration of tau inside the neurons. These observations are contrary to previous 
reports that the cells take up only specific antibodies and the uptake of antibodies is 
dependent on the concentration of the pathological tau inside the neurons (Gu et al., 
2013, Shamir et al., 2016).  
The internalized antibodies were detected as puncta in the cytoplasm (Figure 3.15). 
Since it is known that antibodies are localized in endosomes or lysosomes (Shamir et 
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al., 2016), we checked the localization of the 2B10 antibody. We observed that our 
antibody clearly co-localized with lysosomal markers. All other internalized antibodies 
also co-localized with the lysosomes (Figure 3.16). A likely reason is that the 
internalized antibodies are degraded in the lysosomes whether they are specific to tau 
protein or not. We observed that only the 2B10 antibody was able to bind to tau 
(TauRDΔK) in the cytosol and in the lysosomes but the control antibody did not bind to 
tau (Figure 3.17). The 2B10 antibody bound to tau was localized in lysosomes 
presumably for degradation. This data is consistent with the previous findings that the 
endosomal–lysosomal pathway is involved in antibody-mediated clearance of tau 
aggregates (Gu et al., 2013, Krishnamurthy et al., 2011). The mechanism of entry of 
our antibodies into N2a cells is not known yet. In our hands, the blockers used to inhibit 
different modes of endocytosis were toxic to our N2a cell model. Therefore, the 
mechanism of antibody uptake is currently under investigation in other cell systems. 
In spite of the different effects of the antibody actions, it is important to understand the 
mechanism of antibody mediated reduction and clearance of tau aggregates. In 
general tau antibodies could use different mechanisms to eliminate or reduce tau 
protein and hence aggregation. One possibility is that extracellular tau binds to the 
antibodies which can get internalized by microglia cell surface receptors (FcγRII and 
FcγRIII). This could inhibit spreading of tau pathology (Funk et al., 2015). Another 
possibility is the internalization of antibodies by neurons and guiding tau to lysosomes 
for degradation which could reduce intracellular tau and therefore tau aggregation (Gu 
et al., 2013) (Figure 4.1). Anti-tau antibodies (produced by active immunization with 
tau) immobilize extracellular tau to prevent its entry into healthy neurons and engage 
microglia for tau clearance via their effector functions (Novak et al., 2018). Anti-tau 
antibodies can also prevent cell-cell spreading of tau pathology by binding to 
extracellular monomeric or aggregated tau and prevent their entry into neurons (Evans 
et al., 2018).  
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Figure 4.1: Proposed mechanisms of activity of anti-tau antibodies 
Cartoon representation of the proposed mechanistic roles of tau antibodies in combating tau 
pathology in vitro and in vivo models. Intraperitoneally (I.P) injected antibodies cross the blood brain 
barrier and interact with the extra and intracellular tau. Antibodies can bind to the extracellular tau 
aggregates (small fraction) and promote the microglial phagocytosis via the Fcγ receptors for 
extracellular clearance of tau aggregates and thereby preventing the spread of pathological tau. 
Some antibodies are readily taken up by the neurons via the receptor mediated (Fcγ II/III) or receptor 
independent (bulk endocytosis) pathways and are released into the cytosol, where they interact with 
the pathological tau and promote their clearance via endosomal-lysosomal pathway. 
In conclusion, this study focussed on the generation of tau oligomer-specific antibodies 
and their uptake into neurons. Different types of antibody can be taken up by cells, but 
only oligomer-specific antibodies bind to tau and form clusters in lysosomes. This 
would be the basis for reducing cytoplasmic tau and thus reducing aggregation. The 
mechanistic details of antibody mediated inhibition of tau-aggregation and clearance 
still has to be elucidated.  
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Appendix 
Chemical composition 
Protein purification chemicals:  
 10 X CB Buffer 
Chemical Weight Stock Volume 
0.2 M Na-Mes 42.646 g - - 
10 mM Na-EGTA 3.804 g 0.5 M 20 ml 
10 mM MgCl2 2 g  1 ml 
Make up to 1 liter with double distilled water, pH 6.8. Store at 4°C. Prepare the whole 
solution once or prepare it from stock. 
 
Re Suspension Buffer Composition: For 100 ml 
Chemical Stock Volume 
CB Buffer 10 X 10 ml 
DTT 1 M 0.5 ml 
PMSF 0.1 M 2 ml 
Leupeptin 10 mg/ml 100 µl 
Pepstatin A 5 mg/ml 200 µl 
benzamidine 1 M 200 µl 
MQ H2O  87 ml 
 
Mono S A Buffer 10 X 
Chemical 10X Stock Volume for 1X 
20 mM Na-MES 0.2 M 100 ml 
50 mM NaCl 5 M 10 ml 
2 mM DTT 1 M 2 ml 
1 mM Na-EGTA 0.5 M 2 ml 
1 mM MgSO4 1 M 1 ml 
0.1 mM PMSF 0.1 M 1 ml 
Make up to 1Liter; pH 6.8; sterilize; PMSF and DTT should be added fresh. 
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Mono S B Buffer (250 ml suffices for a single run) 
Chemical Stock Volume 
20 mM Na-MES 0.2 M 100 ml 
1 M NaCl 5 M 200 ml 
2 mM DTT 1 M 2 ml 
1 mM Na-EGTA 0.5 M 2 ml 
1 mM MgSO4 1 M 1 ml 
0.1 mM PMSF 0.1 M 1 ml 
Make up to 1Liter; pH 6.8; Sterilize; PMSF and DTT should be added fresh. 
 
SDS gel composition 
 
Ingredients 
10% resolving 
gel 
17% resolving 
gel 
4% stacking 
gel 
40% Acrylamide 15 ml 25.6 ml 5.4 ml 
1 M Tris HCl pH 8.8 22 ml 22 ml - 
0.25 M Tris HCl pH 6.8 - - 27 ml 
H2O 22 ml 11.5 ml - 
H2O + bromophenol 
blue 
 
- 
 
- 
20.9 ml 
10 % SDS 600 µl 600 µl 540 µl 
TEMED 120 µl 120 µl 108 µl 
10% APS 65 µl 65 µl 150 µl 
 
5X SDS sample buffer 
0.32 M Tris-HCl, pH 6.8; 10% SDS; 50% glycerol; 1.43 M ß-ME; and  
10
-2
% bromophenol blue 
 
1X SDS running buffer 
0.25 M Tris; 0.192 M glycine; 0.1% SDS;  Make the volume up to 10 liters with doubly 
distilled water. 
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10X blotting buffer or Transfer buffer 
390 mM Glycine; 480 mM Tris; 0.3% SDS;  
Make up to 1 liter with doubly distilled water. 
 
1X blotting buffer or Transfer buffer 
100 ml of 10X blotting buffer; 50 ml 100% methanol;  
Make up to 1 liter with doubly distilled water. 
 
10X TBST 
100 mM Tris; 1.5 M NaCl; 0.5% Tween 20; Make up to 2.5 liters with doubly distilled 
water. Adjust the pH to 7.5 
 
Stripping buffer 
0.2 M glycine; 1 mM EDTA-Na; 0.5 M NaCl, pH 2.5. 
 
Coomassie Stain 
25% isopropanol; 10% acetic acid; 0.05% coomassie R-250; 
Make up to 200 ml with doubly distilled water. 
 
Coomassie destaining solution 
Intensive 
2.5 L ethanol; 2.0 L doubly distilled water; and 0.5 L acetic acid 
Normal: 
250 ml ethanol; 375 ml acetic acid; and 4375 ml doubly distilled water 
 
Silver staining: 
Fixative: 30% ethanol and 10% acetic acid 
Cross-linking reagent: 30% ethanol; 0.5 M sodium acetate; 0.2% sodium thiocyanate 
and 0.5% glutaraldehyde 
Silver nitrate staining solution: 0.1% silver nitrate; and 0.02% formaldehyde 
Developing solution: 2.5% sodium carbonate; 0.01% formaldehyde. 
Reaction ending solution: 50 mM EDTA, pH 8.0 
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AFM 
Adsorption buffer (PBS) 
137 mM NaCl; 8 mM NH2PO4, 2.7 mM KCl; and 1.5 mM KH2PO4 adjusted to pH 7.4. 
Imaging buffer: 
10 mM Tris–HCl; 50 mM KCl; adjusted to pH 7.4. 
 
Cell culture chemicals 
N2a cells culture medium 
15% FBS; 1% penicillin and streptomycin; 1% NEAA; diluted in MEME medium 
followed by filter sterilization. 
 
N2a cells freezing medium: 
50% FBS; 40% MEME; 10% DMSO; 
Preparation and sterilization using syringe filters.  
 
2X Lysis buffer 
100 mM Tris-HCl, pH 7.4; 20% glycerol ; 2% NP 40 detergent; 10 mM DTT; 2 mM 
EGTA; 40 mM NaF and 2 mM Na3VO4. 
Working lysis buffer 
2X lysis buffer; 150 mM NaCl; 1X complete protease mini; 1X PhosSTOP; 5 mM 
CHAPS. Make up these chemicals with distilled water to the desired volume. 
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I: Plasmid map of (K18DK280) TauRDΔK-Luc-N. 
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II: Plasmid map of (K18DK280) TauRDΔK-Luc-C. 
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